U.S. patent application number 16/422594 was filed with the patent office on 2019-10-17 for compositions and methods for inhibition of mycobacteria.
The applicant listed for this patent is THE TEXAS A&M UNIVERSITY SYSTEM. Invention is credited to Billy F. McCutchen, Manchi CM Reddy, James C. Sacchettini, Nian E. Zhou.
Application Number | 20190314381 16/422594 |
Document ID | / |
Family ID | 54009646 |
Filed Date | 2019-10-17 |
![](/patent/app/20190314381/US20190314381A1-20191017-C00001.png)
![](/patent/app/20190314381/US20190314381A1-20191017-C00002.png)
![](/patent/app/20190314381/US20190314381A1-20191017-C00003.png)
![](/patent/app/20190314381/US20190314381A1-20191017-C00004.png)
![](/patent/app/20190314381/US20190314381A1-20191017-C00005.png)
![](/patent/app/20190314381/US20190314381A1-20191017-C00006.png)
![](/patent/app/20190314381/US20190314381A1-20191017-C00007.png)
![](/patent/app/20190314381/US20190314381A1-20191017-C00008.png)
![](/patent/app/20190314381/US20190314381A1-20191017-C00009.png)
![](/patent/app/20190314381/US20190314381A1-20191017-C00010.png)
![](/patent/app/20190314381/US20190314381A1-20191017-C00011.png)
View All Diagrams
United States Patent
Application |
20190314381 |
Kind Code |
A1 |
Reddy; Manchi CM ; et
al. |
October 17, 2019 |
COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA
Abstract
A composition comprising a drug selected from the group
consisting of an arylphenoxypropionate derivative, an
aryloxyphenoxyacetate derivative, an aryloxyphenylacetate
derivative, a substituted quinol, or a salt, hydrate, or prodrugs
thereof, or a combination thereof, in an amount and formulation
sufficient to inhibit a mycobacterium is disclosed.
Inventors: |
Reddy; Manchi CM; (College
Station, TX) ; Sacchettini; James C.; (College
Station, TX) ; Zhou; Nian E.; (Naperville, IL)
; McCutchen; Billy F.; (College Station, TX) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
THE TEXAS A&M UNIVERSITY SYSTEM |
College Station |
TX |
US |
|
|
Family ID: |
54009646 |
Appl. No.: |
16/422594 |
Filed: |
May 24, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15248844 |
Aug 26, 2016 |
10300071 |
|
|
16422594 |
|
|
|
|
PCT/US2015/017936 |
Feb 27, 2015 |
|
|
|
15248844 |
|
|
|
|
61946284 |
Feb 28, 2014 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 31/44 20130101;
A61K 31/501 20130101; A61K 31/454 20130101; A61K 31/496 20130101;
A61K 31/498 20130101; A61K 31/423 20130101; A61K 31/4439 20130101;
A61P 31/06 20180101; A61K 31/428 20130101; A61K 31/5377
20130101 |
International
Class: |
A61K 31/5377 20060101
A61K031/5377; A61K 31/501 20060101 A61K031/501; A61K 31/496
20060101 A61K031/496; A61K 31/454 20060101 A61K031/454; A61K 31/423
20060101 A61K031/423; A61K 31/498 20060101 A61K031/498; A61K 31/44
20060101 A61K031/44; A61K 31/428 20060101 A61K031/428; A61K 31/4439
20060101 A61K031/4439 |
Claims
1. A composition comprising a drug selected from the group
consisting of an arylphenoxypropionate derivative, an
aryloxyphenoxyacetate derivative, an aryloxyphenylacetate
derivative, a substituted quinol, or a salt, hydrate, or prodrugs
thereof, or a combination thereof, in an amount and formulation
sufficient to inhibit a mycobacterium.
2. The composition of claim 1, wherein the aryloxyphenoxyacetate
derivative has the following formula: ##STR00190## wherein: R.sub.1
is selected from --OR.sub.5, --NR.sub.6R.sub.7 and
--NH--SO.sub.2--R.sub.8 groups, R.sub.2 and R.sub.3 are
independently selected from hydrogen, alkyl, alkenyl, alkynyl,
cycloalkyl, aryl, and heteroaryl groups; or R.sub.2 and R.sub.3
together are a cycloalkyl group; R.sub.4 is selected from the group
consisting of aryl, heteroaryl, bicycloaryl, and bicycloheteroaryl
groups optionally additionally substituted with from zero to four
substitutions selected independently from halogen, hydroxyl, alkyl,
alkoxy, nitril, nitro, amino, alkylamino, dialkylamino,
dialkylaminoalkyl, carboxy, acyl, carboxamido, alkylsulfoxide,
acylamino, phenyl, benzyl, phenoxy, and benzyloxy groups; R.sub.5
is selected from hydrogen or an alkyl, aryl, or benzyl group that
is optionally additionally substituted with an alkyloxy,
alkylamino, dialkylamino, or acylamino group; R.sub.6 and R.sub.7
are independently selected from hydrogen, alkyl, alkenyl, alkynyl,
cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and alkoxy groups;
or R.sub.6 and R.sub.7 together are a cycloalkyl or
heterocycloalkyl group; and R.sub.8 is an alkyl or aryl group
optionally substituted with halogen.
3. The composition of claim 1, wherein the aryloxyphenacetate
derivative has the following formula: ##STR00191## wherein: R.sub.1
is selected from --OR.sub.5, --NR.sub.6R.sub.7 and
--NH--SO.sub.2--R.sub.8 groups, R.sub.2 and R.sub.3 are
independently selected from hydrogen, alkyl, alkenyl, alkynyl,
cycloalkyl, aryl, and heteroaryl groups; or R.sub.2 and R.sub.3
together are a cycloalkyl group; R.sub.4 is selected from the group
consisting of aryl, heteroaryl, bicycloaryl, and bicycloheteroaryl
groups optionally additionally substituted with from zero to four
substitutions selected independently from halogen, hydroxyl, alkyl,
alkoxy, nitril, nitro, amino, alkylamino, dialkylamino,
dialkylaminoalkyl, carboxy, acyl, carboxamido, alkylsulfoxide,
acylamino, phenyl, benzyl, phenoxy, and benzyloxy groups; R.sub.5
is selected from hydrogen or an alkyl, aryl, or benzyl group that
is optionally additionally substituted with an alkyloxy,
alkylamino, dialkylamino, or acylamino group; R.sub.6 and R.sub.7
are independently selected from hydrogen, alkyl, alkenyl, alkynyl,
cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and alkoxy groups;
or R.sub.6 and R.sub.7 together are a cycloalkyl or
heterocycloalkyl group; and R.sub.8 is an alkyl or aryl group
optionally substituted with halogen.
4. The composition of claim 1, wherein the drug is selected from
the following: ##STR00192##
5. The composition of claim 1, wherein the substituted quinol has
the following formula: ##STR00193## wherein: R.sub.9 is selected
from nitril, hydroxyl, heterocycloaryl and alkyloxy groups; and
R.sub.4 is selected from the group consisting of aryl, heteroaryl,
bicycloaryl, and bicycloheteroaryl groups optionally additionally
substituted with from zero to four substitutions chosen
independently from the group consisting of halogen, hydroxyl,
alkyl, alkyloxy, nitril, nitro, amino, alkylamino, dialkylamino,
dialkylaminoalkyl, carboxy, acyl, carboxamido, alkylsulfoxide,
acylamino, phenyl, benzyl, phenoxy, and benzyloxy groups.
6. The composition of claim 1, wherein the arylphenoxypropionate
derivative is selected from the group consisting of haloxyfop,
quizalofop-p, quizalofop-p-ethyl (IUPAC name: ethyl
(2R)-2-[4-(6-chloroquinoxalin-2-yloxy)phenoxy]propionate),
fenoxaprop-p, fenoxaprop-p-ethyl, or proquizafop.
7. The composition of claim 1, further comprising a
pharmaceutically acceptable carrier, a salt, a buffer, a
preservative, or a solubility enhancer.
8. The composition of claim 1, wherein the mycobacterium is
Mycobacterium tuberculosis or Mycobacterium bovis.
9. A method of inhibiting a mycobacterium comprising: administering
a composition comprising an arylphenoxypropionate derivative, an
aryloxyphenoxyacetate derivative, an aryloxyphenylacetate
derivative, a substituted quinol, or a salt, hydrate, or prodrugs
thereof, or a combination thereof to the mycobacterium in an amount
and for a time sufficient to inhibit the mycobacterium.
10. The method of claim 9, wherein the mycobacterium is
pathogenic.
11. The method of claim 9, wherein the mycobacterium is selected
from the group consisting of Mycobacterium tuberculosis or
Mycobacterium bovis.
12. The method of claim 9, wherein the composition is substantially
nontoxic to animals.
13. The method of claim 9, wherein the composition inhibits the
mycobacterium by inhibiting AccD6.
14. The method of claim 9, wherein the mycobacterium is drug
resistant.
15. The method of claim 9, wherein the mycobacterium is multi-drug
resistant.
16. The method of claim 9, wherein the arylphenoxypropionate
derivative, an aryloxyphenoxyacetate derivative, an
aryloxyphenylacetate derivative, a substituted quinol, or a salt,
hydrate, or prodrugs thereof, or a combination thereof has a
minimum inhibitory concentration of about 10 .mu.M or less.
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] The present application is a continuation application of
U.S. patent application Ser. No. 15/248,844 filed Aug. 26, 2016,
which is a continuation application of PCT International
Application Number PCT/US2015/017936 filed Feb. 27, 2015, which
claims priority to U.S. Provisional Application No. 61/946,284
filed Feb. 28, 2014, the contents of which are hereby incorporated
by reference in their entirety for all purposes.
REFERENCE TO SEQUENCE LISTING SUBMITTED VIA EFS-WEB
[0002] This application includes an electronically submitted
sequence listing in .txt format. The .txt file contains a sequence
listing entitled "2016-11-10 017575.1572 ST25.txt" created on Nov.
10, 2016 and is 652 bytes in size. The sequence listing contained
in this .txt file is part of the specification and is hereby
incorporated by reference herein in its entirety.
TECHNICAL FIELD
[0003] The present disclosure relates to compositions for
inhibition of Mycobacterium, including, but not limited to,
Mycobacterium tuberculosis. In particular, the present disclosure
relates to compositions including one or more arylphenoxypropionate
derivatives, such as, but not limited to, quizalofop, fenoxaprop,
proquizalofop, and haloxyfop, one or more aryloxyphenoxyacetate
derivatives, one or more aryloxyphenylacetate derivatives, and one
or more substituted quinols. The present disclosure also relates to
methods of inhibiting a Mycobacterium bacterium using one or more
arylphenoxypropionate derivatives, one or more
aryloxyphenoxyacetate derivatives, one or more aryloxyphenylacetate
derivatives, and one or more substituted quinols.
BACKGROUND
Tuberculosis
[0004] Tuberculosis is a common, chronic, and frequently fatal
infectious disease caused by various strains of mycobacteria, most
commonly Mycobacterium tuberculosis. Drug-resistance and multi-drug
resistance in tuberculosis is increasing, diminishing the efficacy
of first- and second-line tuberculosis drugs. Drugs used for the
treatment of tuberculosis involve the combination of multiple
agents such as isoniazid, rifampicin, pyrazinamide, ethambutol,
streptomycin, para-ammo salicylic acid, ethionamide, cycloserine,
capreomycin, kanamycin, ciprofloxacin, ofloxacin, thioacetazone,
Rifapentine, Bedaquiline, and Rifampin. The regimen recommended by
the US Public Health Service
(http://www.hhs.gov/pharmacy/pp/DHHSpresent/) is a combination of
isoniazid, rifampicin, and pyrazinamide for two months, followed by
isoniazid and rifampicin, together, for another four months. These
drugs are continued for another seven months in patients infected
with HIV. For the treatment of multi-drug resistant tuberculosis,
streptomycin, kanamycin, amikacin, capreomycin, ethionamide,
cycloserine, ciprofloxacin, and ofloxacin are added to the
combination therapies (World Health Organization, Anti-tuberculosis
drug resistance in the world Third Global Report 2004). Currently,
there is neither a single agent nor a combination therapy that can
both treat tuberculosis and shorten the duration of treatment. All
existing approaches to tuberculosis treatment involve the
combination of multiple agents. No single agent exists that is
effective in the clinical treatment of tuberculosis, nor is there
any combination of agents that offer the possibility of a
therapeutic regimen having less than a six month duration. An
urgent need exists for novel and potent inhibitors of pathogenic
mycobacteria.
[0005] Mycobacterium tuberculosis (Mtb) is characterized by an
unusually lipid-rich cell wall of low permeability which allows the
bacterium to survive in the hostile environment of the macrophage
and cause infection. Mycobacterial lipids are essential for both
viability and pathogenicity.
[0006] The first step of fatty-acid biosynthesis is mediated by
acyl-CoA carboxylase (ACC). ACC catalyzes the carboxylation
reaction of acetyl-CoA to produce malonyl-CoA, a precursor in long
chain fatty acid biosynthesis. These fatty acids are essential for
survival, virulence, and antibiotic resistance in Mtb. In
particular, the D6 carboxyltransferase .beta.-subunit (AccD6) has
been shown to be essential to pathogenic mycobacteria, indicating
that this enzyme represents an ideal target for inhibition. The
AccD6 gene in M. bovis shares complete sequence identity with that
of Mtb.
[0007] Most bacteria have a multi-subunit ACC composed of three
functional polypeptides: BC (AccC), BCCP (AccB), and CT (AccA plus
AccD) (2). For example, in Escherichia coli and Staphylococcus
aureus, these Accs are composed of three independent (BC, BCCP, and
CT) functional proteins (2). In yeast and mammals, these functions
are carried out by a single polypeptide with distinct BC, BCCP, and
CT domains (3). In comparison, the Mtb genome contains three BC
.alpha.-subunits (AccA1 to Acc3) and six CT .beta.-subunits (AccD1
to D6) (14). The high number of .beta.-subunits is unusual as other
bacteria generally only have 1-2 ACCases. The multiple
.beta.-subunits likely reflect the ability of mycobacteria to
carboxylate other distinct substrates, including the short acyl
CoAs used as intermediates in glycolipid biosynthesis. Therefore,
the presence of multiple AccA and AccD genes contained within the
Mtb genome is thought to be linked to the wide variety of lipids
found in Mtb.
ACC Inhibitors
[0008] Arylphenoxypropionate derivatives are potent inhibitors of
ACCs, and several arylphenoxypriopionate derivatives, including
haloxyfop, are currently used in herbicides in light of their
species-dependent ACC inhibition. Commercially available
arylphenoxypropionate derivatives exhibit little human toxicity.
Quizalofop-p-ethyl, for example, has LD.sub.50 values of 1753 to
2350 mg/kg in male mice and 1805 to 2360 mg/kg in female mice. In
rabbits, it was reported that LD.sub.50 values were greater than
2,000 mg/kg. Also it was shown in a 1-year feeding study on dogs
that doses of up to 10 mg/kg/day caused zero observed effects. This
compound is rapidly broken down in mammals; more than 90% of a
single oral dose is eliminated in urine within three days. The
Carcinogenicity Peer Review Committee CPRC has classified
quizalofop ethyl as a Group D carcinogen (i.e., not classifiable as
to human cancer potential). To date, however, there are no
bacterial ACC inhibitors in clinical use as antibiotics.
SUMMARY
[0009] The present disclosure, in certain embodiments, relates to
compositions for inhibiting a mycobacterium comprising one or more
arylphenoxypropionate derivatives, one or more
aryloxyphenoxyacetate derivatives, one or more aryloxyphenylacetate
derivatives, one or more substituted quinols, or pharmaceutically
acceptable salts, hydrates, or prodrugs thereof, or combinations
thereof. The compositions are operable to inhibit a pathogenic
mycobacterium.
[0010] According to certain embodiments, the disclosure provides
methods of inhibiting a mycobacterium by administering one or more
arylphenoxypropionate derivatives, one or more
aryloxyphenoxyacetate derivatives, one or more aryloxyphenylacetate
derivatives, one or more substituted quinols, or pharmaceutically
acceptable salts, hydrates, or prodrugs thereof, or combinations
thereof to the mycobacterium in an amount and for a time sufficient
to inhibit the mycobacterium.
[0011] According to certain embodiments, the disclosure provides
methods of inhibiting a mycobacterial ACC by administering one or
more arylphenoxypropionate derivatives, one or more
aryloxyphenoxyacetate derivatives, one or more aryloxyphenylacetate
derivatives, one or more substituted quinols, or pharmaceutically
acceptable salts, hydrates, or prodrugs thereof, or combinations
thereof, to the mycobacterium in an amount and for a time
sufficient to inhibit the mycobacterial ACC.
[0012] According to certain embodiments, the disclosure provides
methods of inhibiting a mycobacterial AccD6 by administering one or
more arylphenoxypropionate derivatives, one or more
aryloxyphenoxyacetate derivatives, one or more aryloxyphenylacetate
derivatives, one or more substituted quinols, or pharmaceutically
acceptable salts, hydrates, or prodrugs thereof, or combinations
thereof, to the mycobacterium in an amount and for a time
sufficient to inhibit the mycobacterial AccD6.
[0013] The following abbreviations are used throughout the
specification:
[0014] Mtb--Mycobacterium tuberculosis
[0015] AccD6--Acetyl-CoA carboxyltransferase .beta.-subunit D6
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] The patent or application file contains at least one drawing
executed in color. Copies of this patent or patent application
publication with color drawing(s) will be provided by the Office
upon request and payment of the necessary fee.
[0017] A more complete understanding of the present embodiments and
advantages thereof may be acquired by referring to the following
description taken in conjunction with the accompanying drawings,
which depict embodiments of the present disclosure, and in which
like numbers refer to similar components, and in which:
[0018] FIG. 1A illustrates schematically the crystal structure of
the haloxyfop-bound Mtb holoenzyme.
[0019] FIG. 1B illustrates schematically the crystal structure of a
single Mtb AccD6 apo subunit.
[0020] FIG. 1C illustrates schematically the superimposed crystal
structures of the first and second Mtb AccD6 apo subunits.
[0021] FIG. 2A illustrates schematically the electron density of
haloxyfop ligands.
[0022] FIG. 2B illustrates schematically the interaction of
haloxyfop with the first Mtb AccD6 binding site.
[0023] FIG. 2C illustrates schematically the interaction of
haloxyfop with the second Mtb AccD6 binding site.
[0024] FIG. 3A is a plot of haloxyfop-R binding to Mtb AccD6.
[0025] FIG. 3B is a graph of the thermodynamic discrimination
profile of haloxyfop-R binding to Mtb AccD6.
[0026] FIG. 4 illustrates the plasma concentration of NZ-331 in
blood samples collected from mice following administration of
NZ-331 dissolved in canola oil by gavage at a dosage of 100
mg/kg.
[0027] FIG. 5 illustrates the plasma concentration of NZ-332 in
blood samples collected from mice following administration of
NZ-332 dissolved in canola oil by gavage at a dosage of 100
mg/kg.
[0028] FIG. 6A illustrates the plasma concentration of NZ-331 and
NZ-332 in blood samples collected from mice following
administration of two doses of NZ-331 and NZ-332 dissolved in
canola oil by gavage at a dosage of 200 mg/kg.
[0029] FIG. 6B illustrates the corrected plasma concentration of
NZ-331 in blood samples collected from mice following
administration of two doses of NZ-331 and NZ-332 dissolved in
canola oil by gavage at a dosage of 200 mg/kg.
[0030] FIG. 7 illustrates the plasma concentration of NZ-313 in
blood samples collected from mice following administration of two
doses of NZ-313 dissolved in canola oil by gavage at a dosage of
100 mg/kg.
[0031] FIG. 8 illustrates the plasma concentration of NZ-313 in
blood samples collected from mice following administration of a
single dose of NZ-313 dissolved in polyethylene glycol (PEG) by
gavage at a dosage of 200 mg/kg.
[0032] FIG. 9 provides a comparison of the plasma concentration of
NZ-313, NZ-313 acid, NZ-313 glucuronidated, NZ331, and NZ-332 in
blood samples collected from mice following administration of a
single dose of 100 mg/kg.
[0033] FIG. 10 illustrates the plasma concentration of NZ-369 in
blood samples collected from mice following administration of a
single dose of NZ-369 dissolved in canola oil by gavage at a dosage
of 200 mg/kg.
[0034] FIG. 11 provides a comparison of the plasma concentrations
NZ-331, NZ-332, and NZ-369 in blood samples collected from mice
following administration of two doses of NZ-331, NZ-332, and NZ-369
dissolved in canola oil at a dosage of 200 mg/kg 8 hours apart.
DETAILED DESCRIPTION
[0035] The present disclosure relates to compositions and methods
for inhibition of a mycobacterium. These compositions and methods
are described in further detail below.
[0036] Unless otherwise indicated by the specific context of this
specification, a mycobacterium may include any species of the genus
Mycobacterium. Furthermore, it may include a mycobacterium in a
patient. The patient may be any animal. In particular, the patient
may be a mammal, such as a human, a pet mammal such as a dog or
cat, an agricultural mammal, such as a horse, cow, buffalo, deer,
pig, sheep, or goat, or a zoo mammal. Although many embodiments
herein are expressed in terms of a single mycobacterium, the same
or similar effects may be seen in groups of mycobacteria in a
patient.
[0037] Mycobacterial inhibition, unless otherwise indicated by the
specific context of this specification, can include killing the
mycobacterium, such as via apoptosis or necrosis, reducing or
arresting the growth of the mycobacterium, rendering the
mycobacterium more susceptible to the immune system, preventing or
reducing mycobacterial infection, reducing the number of
mycobacteria in a patient, or otherwise negatively affecting a
mycobacterium.
Compositions
[0038] The present disclosure includes antimycobacterial
compositions including one or more arylphenoxypropionate
derivatives, one or more aryloxyphenoxyacetate derivatives, one or
more aryloxyphenylacetate derivatives, one or more substituted
quinols, or pharmaceutically acceptable salts, hydrates, or
prodrugs thereof, or combinations thereof.
[0039] In certain embodiments, the present disclosure provides
arylphenoxypropionate derivatives according to one of the following
structures:
##STR00001##
haloxyfop (IUPAC name:
(RS)-2-{4-[3-chloro-5-(trifluoromethyl)-2-pyridyloxy]phenoxy}propionic
acid);
##STR00002##
quizalofop-p (IUPAC name:
(R)-2-[4-(6-chloroquinoxalin-2-yloxy)phenoxy]propionic acid);
##STR00003##
quizalofop-p-ethyl (IUPAC name: ethyl
(2R)-2-[4-(6-chloroquinoxalin-2-yloxy)phenoxy]propionate);
##STR00004##
fenoxaprop-p (IUPAC name:
(R)-2-[4-(6-chlorobenzoxazol-2-yloxy)phenoxy]propionic acid;
##STR00005##
fenoxaprop-p-ethyl (IUPAC name: ethyl
(R)-2-[4-(6-chlorobenzoxazol-2-yloxy)phenoxy]propionate); or
##STR00006##
proquizafop (IUPAC name: 2-isopropylideneaminooxyethyl
(R)-2-[4-(6-chloroquinoxalin-2-yloxy)phenoxy]propionate); and
enantiomers of the general structures.
[0040] In certain embodiments, the present disclosure provides
aryloxyphenoxyacetate derivatives according to the following
structure:
##STR00007##
wherein R.sub.1 is selected from --OR.sub.5, --NR.sub.6R.sub.7 and
--NH--SO.sub.2--R.sub.8 groups, R.sub.2 and R.sub.3 are
independently selected from hydrogen, alkyl, alkenyl, alkynyl,
cycloalkyl, aryl, and heteroaryl groups; or R.sub.2 and R.sub.3
together are a cycloalkyl group; R.sub.4 is selected from the group
consisting of aryl, heteroaryl, bicycloaryl, and bicycloheteroaryl
groups optionally additionally substituted with from zero to four
substitutions selected independently from halogen, hydroxyl, alkyl,
alkoxy, nitril, nitro, amino, alkylamino, dialkylamino,
dialkylaminoalkyl, carboxy, acyl, carboxamido, alkylsulfoxide,
acylamino, phenyl, benzyl, phenoxy, and benzyloxy groups; R.sub.5
is selected from hydrogen or an alkyl, aryl, or benzyl group that
is optionally additionally substituted with an alkyloxy,
alkylamino, dialkylamino, or acylamino group; R.sub.6 and R.sub.7
are independently selected from hydrogen, alkyl, alkenyl, alkynyl,
cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and alkoxy groups;
or R.sub.6 and R.sub.7 together are a cycloalkyl or
heterocycloalkyl group; and R.sub.8 is an alkyl or aryl group
optionally substituted with halogen.
[0041] In certain embodiments, the present disclosure provides
aryloxyphenylacetate derivatives according to the following
structure:
##STR00008##
wherein R.sub.1 is selected from --OR.sub.5, --NR.sub.6R.sub.7 and
--NH--SO.sub.2--R.sub.8 groups, R.sub.2 and R.sub.3 are
independently selected from hydrogen, alkyl, alkenyl, alkynyl,
cycloalkyl, aryl, and heteroaryl groups; or R.sub.2 and R.sub.3
together are a cycloalkyl group; R.sub.4 is selected from the group
consisting of aryl, heteroaryl, bicycloaryl, and bicycloheteroaryl
groups optionally additionally substituted with from zero to four
substitutions selected independently from halogen, hydroxyl, alkyl,
alkoxy, nitril, nitro, amino, alkylamino, dialkylamino,
dialkylaminoalkyl, carboxy, acyl, carboxamido, alkylsulfoxide,
acylamino, phenyl, benzyl, phenoxy, and benzyloxy groups; R.sub.5
is selected from hydrogen or an alkyl, aryl, or benzyl group that
is optionally additionally substituted with an alkyloxy,
alkylamino, dialkylamino, or acylamino group; R.sub.6 and R.sub.7
are independently selected from hydrogen, alkyl, alkenyl, alkynyl,
cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and alkoxy groups;
or R.sub.6 and R.sub.7 together are a cycloalkyl or
heterocycloalkyl group; and R.sub.8 is an alkyl or aryl group
optionally substituted with halogen.
[0042] In certain embodiments, the present disclosure provides
substituted quinols according to the following structure:
##STR00009##
wherein R.sub.9 is selected from nitril, hydroxyl, heterocycloaryl
and alkyloxy groups; and R.sub.4 is selected from the group
consisting of aryl, heteroaryl, bicycloaryl, and bicycloheteroaryl
groups optionally additionally substituted with from zero to four
substitutions chosen independently from the group consisting of
halogen, hydroxyl, alkyl, alkyloxy, nitril, nitro, amino,
alkylamino, dialkylamino, dialkylaminoalkyl, carboxy, acyl,
carboxamido, alkylsulfoxide, acylamino, phenyl, benzyl, phenoxy,
and benzyloxy groups.
[0043] Specific compounds of the invention include those named in
Table 1 and characterized in the examples herein.
TABLE-US-00001 TABLE 1 Arylphenoxypropionate Derivatives WuXi-N8
##STR00010## 1-{5-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]pyridin-2-yl}-3-(propan-2-yl)urea WuXi-N7 ##STR00011##
1-{6-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]pyridazin-3-yl}-3-(propan-2-yl)urea WuXi-N6 ##STR00012##
1-{6-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]pyridin-3-yl}-3-(propan-2-yl)urea WUXI-N5 ##STR00013##
3-{4-[(6-chloro-1,3-benzothiazol-2- yl)oxy]piperidin-1-yl}-N-
methoxypropanamide WUXI-N4 ##STR00014##
2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]piperidin-1-yl}-N-methoxyacetamide quizalofop-p- ethyl
##STR00015## ethyl(2R)-2-{4-[(6-chloroquinoxalin-2-
yl)oxy]phenoxy}propanoate quizalofop-p ##STR00016##
(2R)-2-{4-[(6-chloroquinoxalin-2- yl)oxy]phenoxy}propanoic acid
propaquizafop ##STR00017## 2-{[(propan-2-ylidene)amino]oxy}ethyl 2-
{4-[(6-chloroquinoxalin-2- yl)oxy]phenoxy}propanoate NZ-420
##STR00018## N-{4-[(6-fluoro-1,3-benzothiazol-2-
yl)oxy]phenyl}acetamide NZ-419 ##STR00019##
2-{4-[(6-fluoro-1,3-benzothiazol-2-yl)oxy]-
2-oxo-1,2-dihydropyridin-1-yl}-N- methylacetamide NZ-418
##STR00020## 2-{4-[(6-fluoro-1,3-benzothiazol-2-yl)oxy]-
2-oxo-1,2-dihydropyridin-1-yl}acetic acid NZ-417 ##STR00021##
2-amino-N-{4-[(6-fluoro-1,3-benzothiazol- 2-yl)oxy]phenyl}acetamide
NZ-416 ##STR00022## 3-amino-N-{4-[(6-fluoro-1,3-benzothiazol-
2-yl)oxy]phenyl}propanamide NZ-415 ##STR00023## tert-butyl
N-[({4-[(6-fluoro-1,3-benzothiazol- 2-
yl)oxy]phenyl}carbamoyl)methyl]carbamate NZ-414 ##STR00024##
tert-butyl N-[2-({4-[(6-fluoro-1,3- benzothiazol-2-
yl)oxy]phenyl}carbamoyl)ethyl]carbamate NZ-413 ##STR00025##
4-[(6-fluoro-1,3-benzothiazol-2- yl)oxy]aniline NZ-412 ##STR00026##
tert-butyl N-{4-[(6-fluoro-1,3-benzothiazol-
2-yl)oxy]phenyl}carbamate NZ-411 ##STR00027##
2-{4-[(5,6-difluoro-1,3-benzothiazol-2-
yl)oxy]-2-fluorophenyl}-N-methylacetamide NZ-410 ##STR00028##
2-{2-fluoro-4-[(6-fluoro-1,3-benzothiazol-2-
yl)oxy]phenyl}-N-methylacetamide NZ-409 ##STR00029##
2-{4-[(5,6-difluoro-1,3-benzothiazol-2-
yl)oxy]phenyl}-1-(4-methylpiperazin-1- yl)ethan-1-one NZ-408
##STR00030## 2-{4-[(6-fluoro-1,3-benzothiazol-2-yl)oxy]-
2-hydroxyphenyl}-N-methylpropanamide NZ-407 ##STR00031##
2-{4-[(5,6-difluoro-1,3-benzothiazol-2-
yl)oxy]-2-hydroxyphenyl}-N-(propan-2- yl)acetamide NZ-406
##STR00032## 2-{2-[(6-fluoro-1,3-benzothiazol-2-yl)oxy]-
4-hydroxyphenyl}-N-(propan-2- yl)acetamide NZ-405 ##STR00033##
2-{4-[(6-fluoro-1,3-benzothiazol-2-yl)oxy]-
2-hydroxyphenyl}-N-(propan-2- yl)acetamide NZ-404 ##STR00034##
2-{4-[(6-chloro-1,3-benzothiazol-2-yl)oxy]-
2-oxo-1,2-dihydropyridin-1-yl}-N-(propan- 2-yl)acetamide NZ-403
##STR00035## 2-{4-[(5,6-difluoro-1,3-benzothiazol-2-
yl)oxy]phenyl}-N-(propan-2-yl)acetamide NZ-402 ##STR00036##
2-{4-[(6-chloroquinoxalin-2-yl)oxy]-2-
hydroxyphenyl}-N-methylacetamide NZ-401 ##STR00037##
2-{4-[(5,6-difluoro-1,3-benzothiazol-2- yl)oxy]-2-hydroxyphenyl}-N-
methylacetamide NZ-400 ##STR00038##
2-{4-[(5,6-difluoro-1,3-benzothiazol-2-
yl)oxy]phenyl}-N-methylacetamide NZ-399 ##STR00039##
2-{4-[(5,6-difluoro-1,3-benzothiazol-2- yl)oxy]phenyl}acetic acid
NZ-398 ##STR00040## methyl 2-{4-[(5,6-difluoro-1,3-benzothiazol-
2-yl)oxy]phenyl}acetate NZ-397 ##STR00041##
2-{4-[(6-chloro-1,3-benzothiazol-2-yl)oxy]-
2-oxo-1,2-dihydropyridin-1-yl}acetic acid NZ-396 ##STR00042##
methyl 2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]-2-oxo-1,2-dihydropyridin-1- yl}acetate NZ-395 ##STR00043##
2-{4-[(6-fluoro-1,3-benzothiazol-2-yl)oxy]-
2-hydroxyphenyl}-N-methylacetamide NZ-394 ##STR00044##
2-{4-[(5,6-dichloro-1,3-benzothiazol-2-
yl)oxy]phenyl}-N-methylpropanamide NZ-393 ##STR00045##
1-{4-[(5,6-dichloro-1,3-benzothiazol-2-
yl)oxy]phenyl}-3-(propan-2-yl)urea NZ-392 ##STR00046##
2-{4-[(6-chloro-1,3-benzothiazol-2-yl)oxy]-
2-methoxyphenyl}-N-methylacetamide NZ-391 ##STR00047##
1-{5-[(6-chloro-1,3-benzothiazol-2-yl)oxy]-
1-oxo-1.lamda..sup.5-pyridin-2-yl}-3-(propan-2-yl)urea NZ-390
##STR00048## 2-{2-[(6-chloro-1,3-benzothiazol-2-yl)oxy]-
4-hydroxyphenyl}-N-methylacetamide NZ-389 ##STR00049##
2-{4-[(6-chloro-1,3-benzothiazol-2-yl)oxy]-
2-hydroxyphenyl}-N-methylacetamide NZ-388 ##STR00050##
1-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}-1-methyl-3-(propan-2- yl)urea NZ-387 ##STR00051##
2-{4-[(5,6-difluoro-1,3-benzothiazol-2-
yl)oxy]phenyl}-N-methylpropanamide NZ-386 ##STR00052##
2-{4-[(6-fluoro-1,3-benzothiazol-2-
yl)oxy]phenyl}-N-methylpropanamide NZ-385 ##STR00053##
2-{4-[(6-fluoro-1,3-benzothiazol-2-
yl)oxy]phenyl}-N-methylacetamide NZ-383 ##STR00054##
2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}-N-methylacetamide NZ-382 ##STR00055##
1-{4-[(5,6-difluoro-1,3-benzothiazol-2-
yl)oxy]phenyl}-3-(propan-2-yl)urea NZ-381 ##STR00056##
1-(4-{[6-(hydroxymethyl)-1,3-benzothiazol-
2-yl]oxy}phenyl)-3-(propan-2-yl)urea NZ-380 ##STR00057##
1-{4-[(6-methanesulfonyl-1,3-benzothiazol-
2-yl)oxy]phenyl}-3-(propan-2-yl)urea NZ-379 ##STR00058##
3-(propan-2-yl)-1-(4-{[6-(trifluoromethyl)-
1,3-benzothiazol-2-yl]oxy}phenyl)urea NZ-378 ##STR00059## ethyl
2-(4-{[(propan-2- yl)carbamoyl]amino}phenoxy)-1,3-
benzothiazole-6-carboxylate NZ-377 ##STR00060##
1-{4-[(6-cyano-1,3-benzothiazol-2-
yl)oxy]phenyl}-3-(propan-2-yl)urea NZ-376 ##STR00061##
1-{4-[(5-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}-3-(propan-2-yl)urea NZ-374 ##STR00062##
1-{4-[(4-fluoro-1,3-benzothiazol-2-
yl)oxy]phenyl}-3-(propan-2-yl)urea NZ-373 ##STR00063##
1-{4-[(5-fluoro-1,3-benzothiazol-2-
yl)oxy]phenyl}-3-(propan-2-yl)urea NZ-372 ##STR00064##
2-{4-[(6-chloro-1,3-benzothiazol-2- yl)oxy]phenyl}-N-(2,3-
dihydroxypropyl)propanamide NZ-371 ##STR00065##
2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}-N-(1,3-dihydroxypropan-2- yl)propanamide NZ-370
##STR00066## 2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}-N-(2- hydroxyethyl)propanamide NZ-369 ##STR00067##
2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}-N-methylpropanamide NZ-368 ##STR00068##
2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}-N,N-dimethylpropanamide NZ-366 ##STR00069##
2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}-1-(4-methylpiperazin-1- yl)propan-1-one NZ-365
##STR00070## 2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}-1-(morpholin-4-yl)propan-1- one NZ-364 ##STR00071##
2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}-1-(piperazin-1-yl)propan-1- one NZ-363 ##STR00072##
1-{4-[(6-nitro-1,3-benzothiazol-2-
yl)oxy]phenyl}-3-(propan-2-yl)urea NZ-362 ##STR00073##
1-{4-[(6-hydroxy-1,3-benzothiazol-2-
yl)oxy]phenyl}-3-(propan-2-yl)urea NZ-361 ##STR00074##
1-{4-[(6-methoxy-1,3-benzothiazol-2-
yl)oxy]phenyl}-3-(propan-2-yl)urea NZ-360 ##STR00075##
1-[4-(1,3-benzothiazol-2-yloxy)phenyl]-3- (propan-2-yl)urea NZ-359
##STR00076## 1-{4-[(6-bromo-1,3-benzothiazol-2-
yl)oxy]phenyl}-3-(propan-2-yl)urea NZ-358 ##STR00077##
1-{4-[(6-methyl-1,3-benzothiazol-2-
yl)oxy]phenyl}-3-(propan-2-yl)urea NZ-357 ##STR00078##
2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}-N,2-dimethoxyacetamide NZ-356 ##STR00079##
2-{4-[(6-chloro-1,3-benzothiazol-2- yl)oxy]phenyl}-2-methoxyacetic
acid NZ-355 ##STR00080## methyl 2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}-2-methoxyacetate NZ-354 ##STR00081##
1-{4-[(6-chloro-1,3-benzothiazol-2- yl)oxy]phenyl}-3,3-dimethylurea
NZ-353 ##STR00082## 1-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}-3-methylurea NZ-352 ##STR00083##
4-[(6-chloro-1,3-benzothiazol-2- yl)oxy]aniline NZ-351 ##STR00084##
tert-butyl N-{4-[(6-chloro-1,3-benzothiazol-
2-yl)oxy]phenyl}carbamate NZ-350 ##STR00085##
1-({4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}methyl)-3-methylurea NZ-349 ##STR00086##
1-({4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}methyl)-3,3-dimethylurea NZ-348 ##STR00087##
{4-[(6-chloro-1,3-benzothiazol-2- yl)oxy]phenyl}methanamine NZ-347
##STR00088## tert-butyl N-({4-[(6-chloro-1,3-benzothiazol-
2-yl)oxy]phenyl}methyl)carbamate NZ-346 ##STR00089##
1-{4-[(6-chloroquinolin-2-yl)oxy]phenyl}-3- (propan-2-yl)urea
NZ-345 ##STR00090## 1-{4-[(6-fluoroquinoxalin-2-yl)oxy]phenyl}-
3-(propan-2-yl)urea NZ-344 ##STR00091##
1-{4-[(6-chloroquinoxalin-2-yl)oxy]phenyl}- 3-methoxyurea NZ-343
##STR00092## 1-{4-[(6-chloroquinoxalin-2-yl)oxy]phenyl}-
3,3-dimethylurea NZ-342 ##STR00093##
1-{4-[(6-chloroquinoxalin-2-yl)oxy]phenyl}- 3-methylurea NZ-341
##STR00094## 1-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}imidazolidin-2-one NZ-338 ##STR00095##
2-{4-[(6-chloro-1,3-benzothiazol-2- yl)oxy]phenyl}-2-hydroxy-N-
methoxyacetamide NZ-337 ##STR00096##
2-{4-[(6-chloro-1,3-benzothiazol-2- yl)oxy]phenyl}-2-hydroxyacetic
acid NZ-336 ##STR00097## methyl 2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}-2-hydroxyacetate NZ-335 ##STR00098##
N-methoxy-2-{4-[(6-methoxy-1,3-
benzothiazol-2-yl)oxy]phenyl}propanamide NZ-334 ##STR00099##
2-{4-[(6-methoxy-1,3-benzothiazol-2- yl)oxy]phenyl}propanoic acid
NZ-333 ##STR00100## methyl 2-{4-[(6-methoxy-1,3-benzothiazol-
2-yl)oxy]phenyl}propanoate NZ-332 ##STR00101##
1-{4-[(6-fluoro-1,3-benzothiazol-2-
yl)oxy]phenyl}-3-(propan-2-yl)urea NZ-331 ##STR00102##
1-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}-3-(propan-2-yl)urea NZ-330 ##STR00103##
2-{4-[(6-fluoro-1,3-benzothiazol-2-
yl)oxy]phenyl}-N-methoxypropanamide NZ-329 ##STR00104##
2-{4-[(6-fluoro-1,3-benzothiazol-2- yl)oxy]phenyl}propanoic acid
NZ-328 ##STR00105## methyl 2-{4-[(6-fluoro-1,3-benzothiazol-2-
yl)oxy]phenyl}propanoate NZ-327 ##STR00106##
2-{4-[(6-chloro-1,3-benzothiazol-2- yl)oxy]phenyl}-N-(propan-2-
yl)propanamide NZ-326 ##STR00107## 2-{4-[(6-chloroquinoxalin-2-
yl)oxy]phenoxy}-N-(propan-2- yloxy)acetamide NZ-325 ##STR00108##
(Z)-2-{4-[(6-chloroquinoxalin-2- yl)oxy]phenoxy}-N-
methoxyethenecarbonimidoyl chloride NZ-323 ##STR00109##
2-{4-[(6-chloroquinoxalin-2- yl)oxy]phenoxy}-N-
(cyclopropylmethoxy)acetamide NZ-322 ##STR00110##
1-{4-[(6-chloroquinoxalin-2-yl)oxy]phenyl}- 3-(propan-2-yl)urea
NZ-321 ##STR00111## tert-butyl N-{4-[(6-chloroquinoxalin-2-
yl)oxy]phenyl}carbamate NZ-320 ##STR00112##
N-methoxy-2-oxo-7-phenoxy-2H- chromene-3-carboxamide NZ-319
##STR00113## 2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenoxy}-N-methoxy-2- methylpropanamide NZ-318 ##STR00114##
2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenoxy}-2-methylpropanoic acid NZ-317 ##STR00115## methyl
2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenoxy}-2-methylpropanoate NZ-316 ##STR00116##
2-{4-[(6-chloroquinoxalin-2- yl)oxy]phenoxy}-N-methoxy-2-
methylpropanamide NZ-315 ##STR00117## 2-{4-[(6-chloroquinoxalin-2-
yl)oxy]phenoxy}-2-methylpropanoic acid NZ-314 ##STR00118## methyl
2-{4-[(6-chloroquinoxalin-2- yl)oxy]phenoxy}-2-methylpropanoate
NZ-313 ##STR00119## 2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}-N-methoxypropanamide NZ-312 ##STR00120##
2-{4-[(6-chloro-1,3-benzothiazol-2- yl)oxy]phenyl}propanoic acid
NZ-311 ##STR00121## methyl 2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}propanoate NZ-310 ##STR00122##
2-{4-[(6-chloroquinoxalin-2-yl)oxy]phenyl}- N-methoxypropanamide
NZ-309 ##STR00123## 2-{4-[(6-chloroquinoxalin-2-
yl)oxy]phenyl}propanoic acid NZ-308 ##STR00124## methyl
2-{4-[(6-chloroquinoxalin-2- yl)oxy]phenyl}propanoate NZ-307
##STR00125## 2-{4-[(6-chloroquinoxalin-2-
yl)oxy]phenoxy}-N-(propan-2-yl)acetamide NZ-306 ##STR00126##
2-{4-[(6-chloroquinoxalin-2- yl)oxy]phenoxy}-N-ethylacetamide
NZ-305 ##STR00127## 2-{4-[(6-fluoro-1,3-benzothiazol-2-
yl)oxy]phenoxy}-N-methoxyacetamide NZ-304 ##STR00128##
2-{4-[(6-fluoro-1,3-benzothiazol-2- yl)oxy]phenoxy}acetic acid
NZ-303 ##STR00129## methyl 2-{4-[(6-fluoro-1,3-benzothiazol-2-
yl)oxy]phenoxy}acetate NZ-302 ##STR00130## methyl
2-{4-[(6-chloro-1,3-benzoxazol-2- yl)oxy]phenyl}acetate NZ-301
##STR00131## 2-{4-[(6-chloroquinoxalin-2-yl)oxy]phenyl}-
N-methoxyacetamide NZ-300 ##STR00132##
2-{4-[(6-fluoro-1,3-benzothiazol-2-
yl)oxy]phenyl}-N-methoxyacetamide NZ-299 ##STR00133##
2-{4-[(6-fluoro-1,3-benzothiazol-2- yl)oxy]phenyl}acetic acid
NZ-298 ##STR00134## 2-{4-[(6-chloroquinoxalin-2-
yl)oxy]phenyl}acetic acid NZ-297 ##STR00135## methyl
2-{4-[(6-chloroquinoxalin-2- yl)oxy]phenyl}acetate NZ-296
##STR00136## (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-
yl)oxy]phenoxy}-N-methoxypropanamide NZ-295 ##STR00137##
(2R)-2-{4-[(6-chloroquinoxalin-2-
yl)oxy]phenoxy}-N-methoxypropanamide NZ-294 ##STR00138## methyl
2-{4-[(6-fluoro-1,3-benzothiazol-2- yl)oxy]phenyl}acetate NZ-293
##STR00139## 2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}-N-methoxyacetamide NZ-292 ##STR00140##
6-chloro-2-phenoxy-1,3-benzothiazole NZ-291 ##STR00141##
6-chloro-2-(3-methylphenoxy)-1,3- benzothiazole NZ-290 ##STR00142##
2-{4-[(6-chloroquinoxalin-2- yl)oxy]phenoxy}-N-methoxy-N-
methylacetamide NZ-289 ##STR00143##
(2R)-2-{4-[(6-fluoro-1,3-benzothiazol-2-
yl)oxy]phenoxy}-N-methoxypropanamide NZ-288 ##STR00144##
4-[(6-chloro-1,3-benzothiazol-2- yl)oxy]benzoic acid NZ-287
##STR00145## 2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}acetic acid NZ-286 ##STR00146##
2-{4-[(6-chloroquinoxalin-2- yl)oxy]phenoxy}-N-hydroxyacetamide
NZ-285 ##STR00147## methyl 4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]benzoate NZ-284 ##STR00148## methyl
2-{4-[(6-chloro-1,3-benzothiazol-2- yl)oxy]phenyl}acetate NZ-283
##STR00149## (2E)-3-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenyl}prop-2-enoic acid NZ-282 ##STR00150##
3-{4-[(6-chloro-1,3-benzothiazol-2- yl)oxy]phenyl}propanoic acid
NZ-281 ##STR00151## methyl (2E)-3-{4-[(6-chloro-1,3-
benzothiazol-2-yl)oxy]phenyl}prop-2- enoate NZ-280 ##STR00152##
methyl 3-{4-[(6-chloro-1,3-benzothiazol-2- yl)oxy]phenyl}propanoate
NZ-279 ##STR00153## 2-{4-[(6-chloroquinoxalin-2-
yl)oxy]phenoxy}-N-hydroxy-N- methylacetamide NZ-278 ##STR00154##
2-{4-[(6-chloroquinoxalin-2-
yl)oxy]phenoxy}-1-(4-methylpiperazin-1- yl)ethan-1-one NZ-277
##STR00155## 2-{4-[(6-chloroquinoxalin-2-
yl)oxy]phenoxy}-1-(piperazin-1-yl)ethan-1- one NZ-276 ##STR00156##
N-(benzenesulfonyl)-2-{4-[(6- chloroquinoxalin-2-
yl)oxy]phenoxy}acetamide NZ-275 ##STR00157##
2-{4-[(6-chloroquinoxalin-2- yl)oxy]phenoxy}-N-
trifluoromethanesulfonylacetamide NZ-274 ##STR00158##
2-{4-[(6-chloroquinoxalin-2- yl)oxy]phenoxy}-N-methoxyacetamide
NZ-273 ##STR00159## 6-chloro-2-[4-(1H-imidazol-2-
ylmethoxy)phenoxy]quinoxaline NZ-272 ##STR00160##
6-chloro-2-[4-(2,2- diethoxyethoxy)phenoxy]quinoxaline NZ-271
##STR00161## 6-chloro-2-[4-(1,3-oxazol-2-
ylmethoxy)phenoxy]quinoxaline NZ-270 ##STR00162##
6-chloro-2-{4-[(1-methyl-1H-1,2,3,4-
tetrazol-5-yl)methoxy]phenoxy}quinoxaline NZ-269 ##STR00163##
6-chloro-2-{4-[(2-methyl-2H-1,2,3,4-
tetrazol-5-yl)methoxy]phenoxy}quinoxaline NZ-268 ##STR00164##
6-chloro-2-[4-(1H-1,2,3,4-tetrazol-5- ylmethoxy)phenoxy]quinoxaline
NZ-267 ##STR00165## 2-{4-[(6-chloroquinoxalin-2-
yl)oxy]phenoxy}-N-methylacetamide NZ-266 ##STR00166##
2-{4-[(6-chloroquinoxalin-2-
yl)oxy]phenoxy}-1-(morpholin-4-yl)ethan-1- one NZ-265 ##STR00167##
2-{4-[(6-chloroquinoxalin-2-
yl)oxy]phenoxy}-1-(piperidin-1-yl)ethan-1- one NZ-264 ##STR00168##
1-{4-[(6-chloroquinoxalin-2- yl)oxy]phenoxy}propan-2-ol NZ-263
##STR00169## 2-{4-[(6-chloroquinoxalin-2-
yl)oxy]phenoxy}acetonitrile NZ-262 ##STR00170##
2-{4-[(6-chloroquinoxalin-2- yl)oxy]phenoxy}-N,N-dimethylacetamide
NZ-261 ##STR00171## (2R)-2-{4-[(6-nitro-1,3-benzothiazol-2-
yl)oxy]phenoxy}propanoic acid NZ-260 ##STR00172## ethyl
(2R)-2-{4-[(6-nitro-1,3-benzothiazol- 2-yl)oxy]phenoxy}propanoate
NZ-259 ##STR00173## 2-{4-[(6-chloroquinoxalin-2- yl)oxy]phenoxy}-N-
methanesulfonylacetamide NZ-258 ##STR00174##
2-{4-[(6-chloroquinoxalin-2- yl)oxy]phenoxy}acetamide NZ-257
##STR00175## 2-{4-[(6-chloroquinoxalin-2- yl)oxy]phenoxy}acetic
acid NZ-256 ##STR00176## methyl 2-{4-[(6-chloroquinoxalin-2-
yl)oxy]phenoxy}acetate
NZ-255 ##STR00177## (2R)-2-{4-[(6-fluoro-1,3-benzothiazol-2-
yl)oxy]phenoxy}propanoic acid NZ-254 ##STR00178##
(2R)-2-[4-(1,3-benzothiazol-2- yloxy)phenoxy]propanoic acid NZ-253
##STR00179## (2R)-2-{4-[(6-bromo-1,3-benzothiazol-2-
yl)oxy]phenoxy}propanoic acid NZ-252 ##STR00180## ethyl
(2R)-2-[4-(1,3-benzothiazol-2- yloxy)phenoxy]propanoate NZ-251
##STR00181## ethyl (2R)-2-{4-[(6-fluoro-1,3-benzothiazol-
2-yl)oxy]phenoxy}propanoate NZ-250 ##STR00182## ethyl
(2R)-2-{4-[(6-bromo-1,3- benzothiazol-2-yl)oxy]phenoxy}propanoate
NZ-247 ##STR00183## (2R)-2-{4-[(6-chloro-1,3-benzothiazol-2-
yl)oxy]phenoxy}propanoic acid NZ-246 ##STR00184## ethyl
(2R)-2-{4-[(6-chloro-1,3-benzothiazol- 2-yl)oxy]phenoxy}propanoate
fenoxaprop-p-ethyl ##STR00185## ethyl
(2R)-2-{4-[(6-chloro-1,3-benzoxazol- 2-yl)oxy]phenoxy}propanoate
fenoxaprop-p ##STR00186## 2-{4-[(6-chloro-1,3-benzoxazol-2-
yl)oxy]phenoxy}propanoic acid
[0044] The present disclosure also includes pharmaceutically
acceptable salts, hydrates, prodrugs, and mixtures of any of the
above compositions. The term "pharmaceutically acceptable salt"
refers to salts whose counter ion derives from pharmaceutically
acceptable non-toxic acids and bases.
[0045] The arylphenoxypropionate derivatives, aryloxyphenoxyacetate
derivatives, aryloxyphenylacetate derivatives, and substituted
quinols which contain a basic moiety, such as, but not limited to
an amine or a pyridine or imidazole ring, may form salts with a
variety of organic and inorganic acids. Suitable pharmaceutically
acceptable (i.e., non-toxic, physiologically acceptable) base
addition salts for the compounds of the present invention include
inorganic acids and organic acids. Examples include acetate,
adipate, alginates, ascorbates, aspartates, benzenesulfonate
(besylate), benzoate, bicarbonate, bisulfate, borates, butyrates,
carbonate, camphorsulfonate, citrate, digluconates,
dodecylsulfates, ethanesulfonate, fumarate, gluconate, glutamate,
glycerophosphates, hemisulfates, heptanoates, hexanoates,
hydrobromides, hydrochloride, hydroiodides,
2-hydroxyethanesulfonates, isethionate, lactate, maleate, malate,
mandelate, methanesulfonate, 2-naphthalenesulfonates, nicotinates,
mucate, nitrate, oxalates, pectinates, persulfates,
3-phenylpropionates, picrates, pivalates, propionates, pamoate,
pantothenate, phosphate, salicylates, succinate, sulfate,
sulfonates, tartrate, p-toluenesulfonate, and the like.
[0046] The arylphenoxypropionate derivatives, aryloxyphenoxyacetate
derivatives, aryloxyphenylacetate derivatives, and substituted
quinols which contain an acidic moiety, such as, but not limited to
a carboxylic acid, may form salts with variety of organic and
inorganic bases. Suitable pharmaceutically acceptable base addition
salts for the compounds of the present invention include, but are
not limited to, ammonium salts, metallic salts made from calcium,
lithium, magnesium, potassium, sodium and zinc or organic salts
made from lysine, N,N-dialkyl amino acid derivatives (e.g.
N,N-dimethylglycine, piperidine-1-acetic acid and
morpholine-4-acetic acid), N,N'-dibenzylethylenediamine,
chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine
(N-methylglucamine), t-butylamine, dicyclohexylamine, hydrabamine,
and procaine.
[0047] The arylphenoxypropionate derivatives, aryloxyphenoxyacetate
derivatives, aryloxyphenylacetate derivatives, and substituted
quinols, and salts thereof, may exist in their tautomeric form (for
example, as an amide or imino ether). All such tautomeric forms are
contemplated herein as part of the present invention.
[0048] The compounds described herein may contain asymmetric
centers and may thus give rise to enantiomers, diastereomers, and
other stereoisomeric forms. Each chiral center may be defined, in
terms of absolute stereochemistry, as (R)- or (S)-. The present
invention is meant to include all such possible isomers, as well
as, their racemic and optically pure forms. Optically active (R)-
and (S)-, or (D)- and (L)-isomers may be prepared using chiral
synthons or chiral reagents, or resolved using conventional
techniques. When the compounds described herein contain olefinic
double bonds or other centers of geometric asymmetry, and unless
specified otherwise, it is intended that the compounds include both
E and Z geometric isomers.
[0049] Compositions of the present disclosure may also include a
pharmaceutically acceptable carrier, in particular a carrier
suitable for the intended mode of administration, or salts,
buffers, or preservatives. Certain of the compounds disclosed
herein are poorly soluble in water. Accordingly, aqueous
compositions of the present disclosure may include solubility
enhancers. Compositions for oral use may include components to
enhance intestinal absorption. The overall formulation of the
compositions may be based on the intended mode of administration.
For instance, the composition may be formulated as a pill or
capsule for oral ingestion. In other examples, the composition may
be encapsulated, such as in a liposome or nanoparticle.
[0050] Compositions of the present disclosure may contain a
sufficient amount of one or more one or more arylphenoxypropionate
derivatives, one or more aryloxyphenoxyacetate derivatives, one or
more aryloxyphenylacetate derivatives, one or more substituted
quinols, or pharmaceutically acceptable salts, hydrates, or
prodrugs thereof, or combinations thereof, to cause inhibition of a
mycobacterium to occur when the composition is administered to the
mycobacterium. The amount can vary depending on other components of
the composition and their effects on drug availability in a
patient, the amount of otherwise required to inhibit the
mycobacterium, the intended mode of administration, the intended
schedule for administration, any drug toxicity concerns, drug-drug
interactions, such as interactions with other medications used by
the patient, or the individual response of a patient. Many
compositions may contain an amount well below levels at which
toxicity to the patient becomes a concern.
[0051] The amount of arylphenoxypropionate derivative,
aryloxyphenoxyacetate derivative, aryloxyphenylacetate derivative,
substituted quinol, or pharmaceutically acceptable salt, hydrate,
or prodrug thereof, or combination thereof, present in a
composition may be measured in any of a number of ways. The amount
may, for example, express concentration or total amount.
Concentration may be for example, weight/weight, weight/volume,
moles/weight, or moles/volume. Total amount may be total weight,
total volume, or total moles. Typically, the amount may be
expressed in a manner standard for the type of formulation or
dosing regimen used.
Mycobacterium Inhibition Methods
[0052] The present disclosure also provides methods of inhibiting a
mycobacterium using an arylphenoxypropionate derivative,
aryloxyphenoxyacetate derivative, aryloxyphenylacetate derivative,
substituted quinol, or pharmaceutically acceptable salt, hydrate,
or prodrug thereof, or combination thereof. In certain embodiments
in which a mycobacterium is inhibited by administration of an
arylphenoxypropionate derivative, aryloxyphenoxyacetate derivative,
aryloxyphenylacetate derivative, substituted quinol, or
pharmaceutically acceptable salt, hydrate, or prodrug thereof, or
combination thereof, the dosage and administration may be adequate
to allow this inhibition. In certain embodiments, it may consist of
regular administration of an amount of the arylphenoxypropionate
derivative, aryloxyphenoxyacetate derivative, aryloxyphenylacetate
derivative, substituted quinol, or pharmaceutically acceptable
salt, hydrate, or prodrug thereof, or combination thereof, to
maintain a certain level in the patient, the patient's blood,
and/or a tissue in the patient. However, dosage amounts and the
administration schedule may be adjusted based on other components
of the composition and their effects on drug availability in a
patient, the intended mode of administration, the intended schedule
for administration, any drug toxicity concerns, and the patient's
response to the drug.
[0053] Without limiting the compositions and methods of
administration described herein, in certain embodiments, the
arylphenoxypropionate derivative, aryloxyphenoxyacetate derivative,
aryloxyphenylacetate derivative, substituted quinol, or
pharmaceutically acceptable salt, hydrate, or prodrug thereof, or
combination thereof, can exhibit its inhibitory effect on a
mycobacterium by directly or indirectly inhibiting fatty acid
biosynthesis. In certain embodiments, this inhibition is mediated
by binding of the arylphenoxypropionate derivative,
aryloxyphenoxyacetate derivative, aryloxyphenylacetate derivative,
substituted quinol, or pharmaceutically acceptable salt, hydrate,
or prodrug thereof, to a portion of an ACC enzyme in the
mycobacterium. In certain embodiments, the portion of the ACC
enzyme in the mycobacterium is the AccD6 subunit. This portion of
the ACC enzyme has been shown to be necessary for pathogenicity in
mycobacteria. By inhibiting this enzyme subunit, growth, cell wall
lipid content, and cell morphology are disrupted. See Pawelczyk et
al., AccD6, a Key Carboxyltransferase Essential for Mycolic Acid
Synthesis in Mycobacterium tuberculosis, Is Dispensable in a
Nonpathogenic Strain, J. BACTERIOL. 193 (24): 6960-6972 (2011).
[0054] In certain embodiments, the arylphenoxypropionate
derivative, aryloxyphenoxyacetate derivative, aryloxyphenylacetate
derivative, substituted quinol, or pharmaceutically acceptable
salt, hydrate, or prodrug thereof, or combination thereof,
disclosed herein can be used for inhibition of a Gram positive
bacterium. In certain embodiments of the present disclosure, the
Gram positive bacterium is a mycobacterium. The mycobacterium that
undergoes inhibition may be any type of mycobacterium. It may, for
instance, be a pathogenic mycobacterium. In certain embodiments,
the mycobacterium belongs to a species selected from the group
consisting of Mycobacterium tuberculosis, Mycobacterium bovis,
Mycobacterium africanum, Mycobacterium avium, Mycobacterium
chelonae, Mycobacterium fortuitum, Mycobacterium intracellulare,
Mycobacterium kansasii, Mycobacterium microti, Mycobacterium
paratuberculosis, Mycobacterium leprae, Mycobacterium szulgai,
Mycobacterium gordonae, Mycobacterium scrofulaceum, Mycobacterium
lentiflavum, Mycobacterium peregrinum, Mycobacterium marinum,
Mycobacterium abscessus, Mycobacterium xenopi, Mycobacterium
malmoense, and Mycobacterium shimoidei.
[0055] The mycobacterium can be located in any region of the
patient, such as the lung. The mycobacterium may be latent or
active.
[0056] Mycobacterium present in a patient may be inhibited by
delivering the composition to the patient. The mode of delivery may
be selected based on a number of factors, including metabolism of
the arylphenoxypropionate derivative, aryloxyphenoxyacetate
derivative, aryloxyphenylacetate derivative, substituted quinol, or
pharmaceutically acceptable salt, hydrate, or prodrug thereof, or
combination thereof, the mode of administration of other drugs to
the patient, the location and type of mycobacterium to be
inhibited, the health of the patient, ability or inability to use
particular dosing forms or schedules with the patient, preferred
dosing schedule, and ease of administration. In specific
embodiments, the mode of administration may be enteral, such as
orally or by introduction into a feeding tube. In other specific
embodiments, the mode of administration may be parenteral, such as
intravenously or by inhalation.
[0057] The dosage amounts and administration schedule of the
arylphenoxypropionate derivative, aryloxyphenoxyacetate derivative,
aryloxyphenylacetate derivative, substituted quinol, or
pharmaceutically acceptable salt, hydrate, or prodrug thereof, or
combination thereof, can vary depending on other components of the
composition and their effects on drug availability in a patient,
the severity of infection, the intended schedule for
administration, any drug toxicity concerns, and the patient's
response to the drug. In certain embodiments, the amount and
frequency of delivery may be such that levels in the patient remain
well below levels at which toxicity to the patient becomes a
concern. However the amount and frequency may also be such that the
levels of the arylphenoxypropionate derivative,
aryloxyphenoxyacetate derivative, aryloxyphenylacetate derivative,
substituted quinol, or pharmaceutically acceptable salt, hydrate,
or prodrug thereof, or combination thereof in the mycobacterium
temporarily reach or continuously remain at a level sufficient to
induce inhibition of the mycobacterium.
[0058] In certain embodiments, the administration of the
arylphenoxypropionate derivative, aryloxyphenoxyacetate derivative,
aryloxyphenylacetate derivative, substituted quinol, or
pharmaceutically acceptable salt, hydrate, or prodrug thereof, or
combination thereof, is calibrated to reach a threshold
concentration in the plasma or tissue of a patient. Such
calibration can take into consideration experimentally derived
bioavailability, such as the exemplary study data provided below,
as well as the mass of the patient. In certain embodiments, the
threshold concentration is a proportion of the minimum inhibitory
concentration (MIC.sub.50). Representative MIC.sub.50 data for
certain arylphenoxypropionate derivatives are provided below.
[0059] In certain embodiments, and based on one or more of the
considerations discussed, the unit dosage of the
arylphenoxypropionate derivative, aryloxyphenoxyacetate derivative,
aryloxyphenylacetate derivative, substituted quinol, or
pharmaceutically acceptable salt, hydrate, or prodrug thereof, or
combination thereof, is between about 1 mg/kg body weight to about
500 mg/kg body weight. In certain embodiments, the unit dosage is
between about 5 mg/kg to about 350 mg/kg. In certain embodiments,
the unit dosage is between about 10 mg/kg and about 200 mg/kg body
weight.
[0060] In certain embodiments, the arylphenoxypropionate
derivative, aryloxyphenoxyacetate derivative, aryloxyphenylacetate
derivative, substituted quinol, or pharmaceutically acceptable
salt, hydrate, or prodrug thereof, or combination thereof, has an
MIC.sub.50 value against Mycobacterium tuberculosis of about 0.1
.mu.M to about 50 .mu.M, or about 0.3 .mu.M to about 20 .mu.M, or
about 0.35 .mu.M to about 12.5 .mu.M, or about 1 .mu.M to about 10
.mu.M, or about 1 .mu.M to about 15 1.1M, or about 1 .mu.M to about
25 .mu.M.
[0061] The present disclosure further includes methods of
identifying whether an arylphenoxypropionate derivative,
aryloxyphenoxyacetate derivative, aryloxyphenylacetate derivative,
substituted quinol, or pharmaceutically acceptable salt, hydrate,
or prodrug thereof, or combination thereof, is able to inhibit a
mycobacterium. Such methods include preparing or obtaining such a
derivative, applying it to a mycobacterium, and identifying that
the derivative inhibits the mycobacterium.
EXAMPLES
[0062] The following examples are provided to further illustrate
certain embodiments of the disclosure. They are not intended to
disclose or describe each and every aspect of the disclosure in
complete detail and should be not be so interpreted. Unless
otherwise specified, designations of cells lines and compositions
are used consistently throughout these examples.
Example 1--Mtb AccD6 Protein Cloning, Expression, and
Purification
[0063] A 1422 base pair DNA fragment containing the AccD6 gene
(Rv2247) was amplified by PCR using Mtb H37Rv genomic DNA as a
template (BEI Resources, Colorado State University). The following
oligonucleotides were used as the forward and reverse primers,
respectively: 5'-agatgaagccatatgacaatcatggcccccgaggcggttg-3' (SEQ
ID NO: 1) and 5'-agagtaagcttacagcgg gatgttcttgaggcggcc-3' (SEQ ID
NO: 2).
[0064] The amplified DNA fragment was purified using the QTAquick
PCR purification kit (Qiagen), following the manufacturer's
protocol. The purified DNA fragment was digested with NdeI and
HindIII, and then ligated using the corresponding restriction sites
into a pET-28b vector (Novagen) to yield an N-terminal
6.times.(His) tag recombinant vector. BL21 star (DE3) cells were
transformed with the AccD6::pET-28b vector. An overnight culture
was diluted to 1:50 in fresh media and grown to mid-log phase at
37.degree. C. in LB media (Difco).
[0065] The cells were induced with 1 mM (final concentration) IPTG
and grown for 16 h at 16.degree. C. Cells were harvested by
centrifugation. The cell pellet was resuspended in 20 mM Tris-HCl
pH 7.5, 10 mM imidazole, 0.5 M NaCl and 10% glycerol (v/v)
containing 1 mM DNAse, 1 mM MgCl.sub.2, and Complete.TM. EDTA-free
protease inhibitor cocktail (Roche). The cell suspension was
lysated using a French press at 18,000 psi and the resulting cell
lysate was centrifuged at 15,000.times.g at 4.degree. C. for 1 h.
The supernatant was collected and filtered through a 0.2 .mu.m
filter and loaded onto a His-Trap nickel chelating column (GE
Healthcare). (His)6-tagged AccD6 was eluted with a 0.2 L linear
gradient of 75-500 mM imidazole in 20 mM Tris pH 7.5, 0.5 M NaCl,
and 10% glycerol (v/v). The eluted protein was dialyzed overnight
in a solution of 20 mM Tris pH 7.5, 50 mM NaCl, 10% glycerol (v/v),
and 1 mM DTT. The purified protein was concentrated to 14 mg
mL.sup.-1 prior to crystallization. Size-exclusion chromatography
confirmed that AccD6 is a two subunit oligomer in solution (data
not shown).
Example 2--Mtb AccD6 Crystallization and Binding Analysis
[0066] Initial crystallization screening of Mtb AccD6 was performed
via the sitting drop method using the Crystal Screen I and II,
Index, SaltRx (Hampton Research), and Wizard I and II (Emerald
Biosciences) screening kits. Crystals were grown by mixing 3 .mu.L
of protein solution with 2 .mu.L of well solution and equilibrated
by hanging-drop vapor diffusion at 295 K in 24-well Linbro trays
containing 500 .mu.L well solution. Crystals were obtained in 5-7
days. Apo AccD6 was crystallized in 60% tacsimate. The apo crystals
were flash-cooled with Paratone N (Hampton Research, Laguna Niguel,
Calif.) and the X-ray diffraction data were collected at the
Advanced Photon Source beam line 23-ID using a MAR 300 CCD detector
(MarMosaic from Marresearch-Charged Coupled Device). HKL2000 was
used to integrate and scale the diffraction data. Examination of
the diffraction data disclosed that the crystals were twinned in a
pseudo-merohedral manner, and the correct space group was
P2.sub.l2.sub.l2.sub.l. The test for pseudo-merohedral twinning was
accomplished using phenix.xtriage, and phenix.refine was used to
refine twinned data with a twin law of k,h,-l. Diffraction images
also exhibited anisotropy, ellipsoidal truncation and anisotropic
scaling were performed on the data prior to refinement.
[0067] The structure of apo AccD6 was solved by molecular
replacement as implemented in PHASER (University of Cambridge, UK).
The complete PccB protein from S. coelicolor (PDB accession code:
1XNV) was used as a search model with water and ions removed.
[0068] For the formation of the AccD6 inhibitor complexes,
haloxyfop-R was selected as a representative AccD6 inhibitor
compound. Haloxyfop-R dissolved in DMSO as a 100 mM stock solution
was added to the concentrated protein solution at a molar ratio of
5:1, and incubated for 1 h at 16.degree. C. The haloxyfop-R complex
was crystallized with 3.5 M sodium formate. Crystals were
transferred directly to a cryoprotectant (30% ethylene glycol,
Hampton Research) and flash-cooled in a liquid nitrogen stream at
100 K before data collection.
[0069] AccD6-haloxyfop-R diffraction data was collected at the
Advanced Light Source Beamline 5.0.2 (Lawrence Berkeley National
Laboratory, Berkeley, Calif.) with a Quantum 315 charge-coupled
device detector. The HKL2000 program package was used for
integration and scaling of the haloxyfop bound crystals. The AccD6
haloxyfop-R complex structure was solved by molecular replacement
using PHASER with chain A of the apo AccD6 structure as a search
model. All refinement was performed by PHENIX with intermittent
manual model building done in COOT. Refinement statistics are
summarized in Table 1. Geometry of the models was assessed with
MOLPROBITY. All pictures were rendered with PyMol. Structures were
deposited in the Protein Data Bank with the accession codes 4FB8
(for the apo structure) and 4G2R (for the haloxyfop-R bound
structure).
[0070] The crystal structures of apo and haloxyfop-R bound Mtb
AccD6 were determined at 3.0 and 2.3 .ANG. resolution,
respectively. Both structures show very good agreement with the
X-ray diffraction data and excellent stereochemistry as provided in
Table 1.
TABLE-US-00002 TABLE 2 Crystallographic statistics for the Mtb
AccD6- Apo and haloxyfop-R complex structures. Apo Haloxyfop-R Data
Collection Space Group P2.sub.12.sub.12.sub.1 I222 Resolution
50-3.0 63-2.3 Twin Fraction 0.48 NA Unit Cell a, b, c ({acute over
(.ANG.)}) 82.3 .times. 117.8 .times. 82.4 .times. 157.9 126.2
.times. 161.7 Redundancy 11.9 (8.7) 7.0 (6.3) Observations 20652
54918 Observations Test Set 1096 1996 Completeness (%) 97.8 (90.4)
100 (99.0) R.sub.merge 15.2 (88.1) 7.80 (3.90) R.sub.pim 0.02
(0.11) 0.01 (0.14) I/I.sigma. 29.5 (2.83) 12.9 (2.70) Refinement
R.sub.work 23.7 16.6 R.sub.free 30.4 19.8 Number of Atoms Protein
6221 6483 Solvent 5 552 Ligand (including ions) 0 95 Ramachandran
analysis Most favorable + 95.9 99.8 allowed (%) Root mean square
deviation Bond Lengths ({acute over (.ANG.)}) 0.008 0.007 Bond
Angles (o) 1.227 1.118
[0071] Mtb AccD6 is a dimer of identical subunits, each comprising
473 amino acids, differing from what was initially proposed that
all Mtb AccD homologues would adopt a hexameric quaternary
assembly. The protein forms a mixed cc/(3 fold with a total of 17
.alpha.-helices and 16 .beta.-strands that resemble the crotonase
superfamily fold. The crystal structure of apo Mtb AccD6 is
illustrated at FIG. 1A as a ribbon diagram colored by secondary
structure. The crystal structure of haloxyfop-R bound Mtb AccD6 is
illustrated at FIG. 1B. The haloxyfop ligands are depicted as
sticks and balls, and the AccD6 subunits are depicted by
differences in color, both colored by secondary structure. Subunit
1 is colored red, yellow, and green, subunit 2 is colored cyan,
purple, and beige. The protein forms a mixed a/(3 fold with a total
of 17 .alpha.-helices and 16 .beta.-strands that resemble the
crotonase superfamily fold. Unlike the hexameric ring-shaped
architecture found in the structure of AccD5 from Mtb, AccD6 is a
homodimer like the yeast and E. coli ACC CT domains.
Superimposition of the two subunits show a RMSD (root mean square
deviation) value of 1.0 .ANG. (calculation performed using the Ca
atoms of 411 residues) as seen in FIG. 1C. The total surface area
for the two subunit complex is 32,370 .ANG..sup.2, with a buried
surface area of 5,260 .ANG..sup.2 at the subunit interface. Each
subunit of the dimer consists of two domains: the N-terminal domain
(.alpha.-helices 1-7 and .beta.-strands 1-10) and the C-terminal
domain (helices 8-17 and .beta.-strands 11-16). H4 and H5 of the
N-terminal domain of one subunit and H13 and H14 of the C-terminal
domain of the second subunit (FIG. 3A) interact at the dimer
interface.
[0072] The active sites of the Mtb AccD6 enzyme were modeled by
superposition of the Mtb AccD6 apo structure with the previously
reported .beta.-subunit of ACC from S. coelicolor in complex with
acetyl-CoA. The Mtb AccD6 active site is formed by the dimer
interface as shown in FIG. 1A. The entrance to the active site is
an opening measuring approximately 8 .ANG. by 14 .ANG. on the
surface, and it leads to a cavity of approximately 400 .ANG..sup.3.
The cavity defined by H2, H5, H14, as well as the loop between
.beta.15 and H16, expands to allow substrate binding. In the active
site of other species such as the S. coelicolor ACC, the key
catalytic residue consists of two pairs of oxyanion-stabilizing
residues (the oxyanion holes). Gly419 and Ala420 hydrogen bond with
the carbonyl group of biotin, whereas Gly182 and Gly183 hydrogen
bond with the carbonyl group of acetyl-CoA. These four residues are
highly conserved among the CT domains of different species
including Mtb AccD6 (Gly336, Ala367, Gly137, and Gly138). The
adenine and phosphate moieties of acetyl-CoA are apparently exposed
to solvent, where they make contact with the surface of the
protein, while the acyl portion inserts into the cavity of the
protein. The adenine moiety of acetyl-CoA lies next to the loop
preceding .beta.-strand 15 and the loop preceding H4 and H2 from
the adjacent subunit. The adenine NH.sub.2 extension is poised to
hydrogen bond with the backbone oxygen of Ala99, while the adenine
N7 atom is in position to hydrogen bond with Met64. The phosphate
oxygen atoms of acetyl-CoA are positioned to form electrostatic
interactions with Lys401, Lys403, and Lys404. The terminal carbonyl
oxygen atom fits into an oxyanion hole composed of the backbone
nitrogen atom of Gly131 and the nitrogen atom of the ring of the
biotin molecule. The biotin cofactor lies deeper in the cavity next
to the CoA-acyl chain and is largely buried.
[0073] The crystal structure of AccD6 co-crystallized with
haloxyfop-R shows two molecules bound per subunit. Both subunits of
the haloxyfop-bound dimer in the asymmetric unit bear high
similarity with a RMSD value of 0.7 .ANG. (over 438 C.alpha.
atoms). Electron density of the haloxyfop ligands is shown in FIG.
2A, with composite OMIT map electron density (blue contoured at 1
.sigma.) shown in wall eye stereo. The first and second haloxyfop
binding sites are illustrated at FIGS. 2B and 2C, with the ligand
illustrated in yellow and the protein illustrated in green, and
wherein dashes indicate hydrogen bonding and numbers represent
distances in .ANG.. Both haloxyfop-R binding clefts are located at
the subunit interface, contacting both. The first binding site
(designated site 1) locates in a cleft that partially overlaps with
the active site (FIG. 2B). The second binding site (site 2) binds
in a cleft (FIG. 2C), connected to binding site 1 by a small
channel of approximately 6 .ANG. in diameter and 5 .ANG. in
length.
[0074] Site 1 is formed by three helices: encompassing H13, H14,
and H5' (prime designates the other subunit in the dimer). In site
1, the carboxyl end of haloxyfop is solvent exposed, while the
tri-fluoromethylpyridyl is buried deeper to allow hydrophobic
contacts. The tri-fluoromethylpyridyl is held in place by base
stacking between the aromatic side chains of Tyr141 and Tyr326. The
phenyl ring in the center position of haloxyfop makes van der Waals
contacts with Gly366 and Gly137, while the tri-fluoromethyl group
makes hydrophobic interactions with Tyr320. In site 1, the
carboxylate group of haloxyfop forms hydrogen bonds with the
backbone amide of Gly138 (2.8 .ANG.) and Ala99 (3 .ANG.), FIG. 2B.
Site 2 (FIG. 2C) is formed by the C-terminal region of H13, H6',
the N-terminal loop of H6', the C-terminal loop to .beta.-strand 9,
and H5'. This site is similar to site 1 in that it contains a
solvent exposed carboxyl group and a tri-fluoromethylpyridyl ring
that buries deeper into the hydrophobic environment of the protein.
The tri-fluoromethylpyridyl ring forms hydrophobic contacts with
Va1157. The phenyl ring in the center of haloxyfop makes contacts
with Trp334, Va1190, and Ser188. In site 2, haloxyfop only makes
one hydrogen bond: the carboxyl group to the amide backbone of
Trp334 (2.7 .ANG.). The methyl group is positioned to make
hydrophobic contacts with His185. The apo structure and the
haloxyfop bound structure share a global similarity, with the
differences between the structures centralized to the residues and
secondary structural elements surrounding both binding sites.
[0075] Superimposition between the apo and haloxyfop bound
structures reveals a RMSD value of 1.0 .ANG. (performed over 832 Ca
residues) as seen in FIG. 1C. At site 1 (FIG. 2B), both Tyr141 and
Tyr326 adopt different rotamer conformations to accommodate the
stacking interactions with haloxyfop. In comparison with the apo
structure, the phenyl ring in the center of haloxyfop in site 1
forces H5 outward (approximately 1.5 .ANG.), while the carboxyl
group of haloxyfop in site 1 forces the loop between (36 and H4
(bearing residue Ala99) outward by 1.1 .ANG.. In contrast, the
haloxyfop in site 2, by means of the phenyl ring in the center,
displaces H6 by 2.1 .ANG.. Both rings of haloxyfop at site 2 shift
the loop between .beta.9 and H5 (bearing residue 157) outward in
comparison to the apo structure (approximately 1.3 .ANG.). The
tri-fluoromethyl group of haloxyfop at site 2 is located near
Met151, which forms a different rotamer conformation than the apo
structure, and (39 also shifts approximately 1.3 .ANG.. The
flexibility of these residues and secondary structural elements
allow the formation of site 2 in the Mtb structure.
Example 3--In Vitro Mtb AccD6 Inhibition Assay
[0076] AccD6 activity was monitored by measuring the reduction of
NAD.sup.+ dependent of the synthesis of acetyl-CoA, in an assay
coupled to citrate synthase-malate dehydrogenase reaction. The
formation of NADH, which is proportional to the activity of Mtb
ACCD6, was measured spectrophotometrically at 340 nm.
[0077] The reaction catalyzed by AccD6 proceeds in two steps. In
the first step, biotin bound to a biotin carboxylase carrier
protein (BCCP) is carboxylated by biotin carboxylase. Subsequently,
AccD6 catalyzes the transfer of the carboxyl moiety to an
acetyl-CoA molecule to form malonyl-CoA. The reaction is
illustrated schematically below:
##STR00187##
[0078] AccD6 activity was monitored by measurement of the reverse
reaction rate of the reaction catalyzed by the enzyme. Using
malonyl-CoA as a substrate, the formation of acetyl-CoA was coupled
to the citrate synthase-malate dehydrogenase reaction involving the
reduction of NAD.sup.+ (25). This is in accordance to the coupled
reactions:
##STR00188##
where CS and MDH correspond, respectively, to citrate synthase and
malate dehydrogenase. The formation of NADH, which is proportional
to the activity of Mtb AccD6, was measured spectrophotometrically
at 340 nm using a Thermo Scientific Multiscan Go Plate Reader. The
MDH reaction was initially kept in equilibrium in the absence of
AccD6. Addition of AccD6 to the reaction mix, in the presence of
CS, induces oxalacetate consumption by CS and equilibrium shift of
the MDH reaction, leading to the AccD6-dependent formation of NADH.
The reaction, which was carried out in a Corning 384-well plate at
30.degree. C., was monitored for 30 minutes. The 100 .mu.L reaction
contained 0.6 mg mL.sup.-1 BSA, 100 mM potassium phosphate pH 8.0,
20 mM L-malic acid, 0.5 mM NAD.sup.+, 6 mM biocytin, 3.6 U
mL.sup.-1 MDH, 6.8 U mL.sup.-1 CS, and varied concentrations of
malonyl CoA (0 to 40 .mu.M). The kinetic parameters were calculated
at an enzyme concentration of 2 .mu.M and 1% (v/v) DMSO. Data was
fit to the Henri-Michaelis-Menten Equation (HMM):
v=V.sub.max[S]/K.sub.m+[S]
in which v, V.sub.max, [S], and K.sub.m correspond to,
respectively, the steady-state reaction rate, the maximum reaction
rate, substrate concentration, and the HMM constant for substrate
S; using the GraphPad Prism demo version for Windows (GraphPad
Software, La Jolla Calif. USA). The K.sub.m for malonyl-CoA was
calculated to be 390.+-.70 .mu.M, and V.sub.max5.5.+-.0.4
min.sup.-1.
[0079] Enzymatic inhibition by representative arylphenoxypropionate
derivatives, aryloxyphenoxyacetate derivatives,
aryloxyphenylacetate derivatives, and substituted quinols was
tested by repeating the protocol above in the presence of
malonyl-CoA and either 300 or 200 .mu.M of the test inhibitor. The
concentration of the test inhibitors required to reduce the Mtb
AccD6 activity to half of its initial value in the absence of
inhibitor (IC.sub.50) was assigned by the addition of 1 .mu.L of
100.times. inhibitor stock to a 100 .mu.L reaction. 1 .mu.L DMSO
was added to the control reactions (enzyme activity in absence of
inhibitor). The reaction was incubated at room temperature for 20
minutes and was initiated by the addition of 300 .mu.M malonyl-CoA,
in the presence of concentrations of the test inhibitor from 10
.mu.M to 2000 .mu.M. The dose response was measured by calculating
the decrease in initial velocity, and IC.sub.50 values were
assigned according to Equation (2):
v.sub.i/v.sub.o=1/[1+([I]/IC.sub.50).sup.n] (2)
where v.sub.i/v.sub.o, [I], and n correspond to, respectively,
enzyme fractional activity in presence of inhibitor l, inhibitor
concentration, and the Hill's coefficient. The IC.sub.50 values for
the representative compounds are provided in Table 3 below.
[0080] Preliminary studies of commercially available herbicides
indicated that of clodinofop, cyhalofop, haloxyfop, fluazifop, and
diclofop (from the fop family); and sethoxydim, alloxydim,
cycloxydim, tepraloxydim, and tralkoxydim (from the dim family),
only haloxyfop exhibited Mtb AccD6 inhibition, and none exhibited
whole Mycobacterium tuberculosis cell inhibition.
Example 4--Isothermal Titration Calorimetry (ITC)
[0081] The binding of haloxyfop-R to Mtb AccD6 was further
characterized by ITC measurements to determine the stoichiometry of
interaction (n) and the dissociation constant (K.sub.d). The ITC
plot obtained from titration of haloxyfop-R is displayed in FIG.
3A. Data was best fitted to the single mode data analysis option
giving an n value of 1.83.+-.0.03 and a molar ratio of 2:1. The n
value suggests that two molecules of haloxyfop-R bind per subunit,
consistent with the presence of two haloxyfop-R binding sites per
subunit observed in the crystal structure. The K.sub.d value of
35.84.+-.1.38 .mu.M is in good agreement with the kinetically
determined IC.sub.50. These results are indicative of the presence
of two binding sites on each subunit.
[0082] The thermodynamic discrimination profile for haloxyfop
binding (.DELTA.H=-9300 cal/mol; -T.DELTA.S=3122 cal/mol/degree;
.DELTA.G=-6177 cal/mol) is illustrated at FIG. 3B, and is plotted
as a single binding event, as explained above. The profile
indicates that its interaction with AccD6 is mostly enthalpic
driven (due to hydrogen bond donors and acceptors good placement on
both binding sites, as well as due to favorable van der Waals
interactions), and presents unfavorable entropy (due to haloxyfop
flexibility and high polarity).
Example 5--In Vitro Mtb Inhibition Assay
[0083] A whole-cell assay was used to evaluate growth inhibition of
the Mtb strain mc.sup.2-7000 by each of the arylphenoxypropionate
derivatives of the table below. The inhibitory activity against Mtb
whole cells was evaluated against MC.sup.2-7000 strain cultures (10
mL Difco 7H9, 100 .mu.L dextrose, 1 mL OADC, 85 .mu.L NaCl (10%
solution), 25 .mu.L Tween 80, 10 .mu.L of Malachite Green (0.25
mg/mL), and 1 mM pantothenic acid), grown for 3 days, and diluted
to OD.sub.600 0.005. Each compound was tested over a range from 100
.mu.M-100 nM. After 6 days of incubation at 37.degree. C., culture
plates were stained with resazurin and read on the 7.sup.th day.
The IC.sub.50 and MIC for the representative arylphenoxypropionate
derivatives is provided in Table 2. These values are comparable to
those of currently employed tuberculosis drugs, which have MIC
values in the low micromolar range.
TABLE-US-00003 TABLE 3 IC.sub.50 and MIC for Arylphenoxypropionate
Derivatives for Mtb Strain mc.sup.2-7000 Compound IC.sub.50 (.mu.M)
MIC (.mu.M) fenoxaprop-p 1.5 25 fenoxaprop-p-ethyl N/A 1.56
haloxyfop-p 21.4 N/A NZ-246 N/A 3 NZ-247 2.5 N/A NZ-250 N/A 3.12
NZ-251 N/A 0.23 NZ-252 Not Soluble Not Soluble NZ-253 >15 N/A
NZ-254 >15 N/A NZ-255 1.2 N/A NZ-256 N/A 1.5 NZ-257 1.5-1.9 N/A
NZ-258 2.1-3.1 50 NZ-259 1.6-2.6 >50 NZ-260 N/A 0.19-2.3 NZ-261
1.8 N/A NZ-262 1.8 >25 NZ-263 7.8 >50 NZ-264 3.4 >12.5
NZ-265 0.57 3 NZ-266 0.99 >12.5 NZ-267 2.4 >25 NZ-268 1.7
>12.5 NZ-269 15.8 >50 NZ-270 9.7 >50 NZ-271 11.6 >50
NZ-272 5.8 >12.5 NZ-273 7.9 >25 NZ-274 3.7 0.173 NZ-275 3.8
12.5 NZ-276 7.3 3.1 NZ-277 5.6 12.5 NZ-278 1.1 3.1 NZ-279 0.8
>50 NZ-280 50% inhibition at 20 uM 6 NZ-281 30% inhibition at 20
uM 50 NZ-282 40% inhibition at 20 uM Not Active NZ-283 33%
inhibition at 20 uM 12 NZ-284 17 4.5 NZ-285 Not Active 12 NZ-286
1.4 3 NZ-287 0.52 12 NZ-288 12 25 NZ-289 6.1 0.35 NZ-290 2.5 1.5
NZ-291 30% inhibition at 20 uM 25 NZ-292 42% inhibition at 20 uM 12
NZ-293 1 3 NZ-294 12.5 3 NZ-295 0.93 4.5 NZ-296 1.8 3 NZ-297 10 12
NZ-298 0.28 25 NZ-299 0.324 12 NZ-300 0.82 7.5 NZ-301 0.265 12
NZ-302 50% inhibition at 20 uM 3 NZ-303 50% inhibition at 20 uM 4.5
NZ-304 3.4 25 NZ-305 50% inhibition at 15 uM 3 NZ-306 4.6 25 NZ-307
2.5 3 NZ-308 8 4.5 NZ-309 0.172 12 NZ-310 0.182 6 NZ-311 10 3
NZ-312 0.26 6 NZ-313 0.32 (racemic mixture) 0.38 NZ-314 17.5 6
NZ-315 1.7 25 NZ-316 15 6 NZ-317 15 6 NZ-318 1.5 12 NZ-319 20 6
NZ-320 20 50 NZ-321 20 50 NZ-322 0.092 12 NZ-323 3.6 6 NZ-325 0.63
3 NZ-326 2.5-4.4 3 NZ-327 0.3 12 NZ-328 10 12 NZ-329 0.37 12 NZ-330
0.24 (racemic mixture) 1.5 NZ-331 0.8 0.8 NZ-332 0.65 0.8 NZ-333
12.5 12 NZ-334 10 25 NZ-335 15 12 NZ-336 15 12 NZ-337 2.3 25 NZ-338
7.2 25 NZ-341 2.6 12 NZ-342 0.6 50 NZ-343 0.4 25 NZ-344 4.1 25
NZ-345 0.5 25 NZ-346 0.4 50 NZ-347 Not Active 15 NZ-348 Not Active
2 NZ-349 7 8 NZ-350 1.6 Not Active NZ-351 Not Active Not Active
NZ-352 Not Active 1.5 NZ-353 4 Not Active NZ-354 7.3 1 NZ-355 20
4.5 NZ-356 1.7 25 NZ-357 3.6 20 NZ-358 20 5.8 NZ-359 8.4 >50
NZ-360 13.3 4.3 NZ-361 19% inhibition at 20 uM 3.2 NZ-362 20%
inhibition at 20 uM 6.5 NZ-363 4.7 >50 NZ-364 20% inhibition at
20 uM 1.34 NZ-365 6.2 18.88 NZ-366 4.9 0.56 NZ-368 3.6 2.07 NZ-369
0.87 0.73-0.98 NZ-370 1 1.8 NZ-371 0.86 19.97 NZ-372 2.75 4.67
NZ-373 1.66 Not Active NZ-374 Not Active Not Active NZ-376 0.874
Not Active NZ-377 7.9 Not Active NZ-378 Not Active 2.2 NZ-379 Not
Active Not Active NZ-380 Not Active 3.4 NZ-381 Not Active 7.3
NZ-382 0.27-0.35 Not Active NZ-383 0.8-1.17 3.9 NZ-385 0.87 3
NZ-386 0.62 1.1-2.1 NZ-387 0.26 2.7-8 NZ-388 3 2.1 NZ-389 0.21
1.2-2.2 NZ-390 15.4 Not Active NZ-391 Not Active Not Active NZ-392
7.18 7.28 NZ-393 5.07 ND NZ-394 0.98 Not active NZ-395 0.16 0.6-0.9
NZ-396 11.35 6.19-8.6 NZ-397 0.45 Not Active NZ-398 3.6 0.89 NZ-399
0.18 1.36 NZ-400 0.21 0.61 NZ-401 0.12 0.54 NZ-402 0.21 2.16 NZ-403
0.16 1.24 NZ-404 14.36 38% at 50 uM NZ-405 0.15 17.5 NZ-406 Not
Active 46% at 50 uM NZ-407 0.11 11.7 NZ-408 0.21 6.5 NZ-409 0.66
N/A NZ-410 0.38 N/A NZ-411 0.24 N/A NZ-412 17% at 20 uM ND NZ-413
14 ND NZ-414 15 ND NZ-415 20 ND NZ-416 20% at 20 uM ND NZ-417 10%
at 20 uM ND propaquizafop 2.1 1.56 quizalofop-p 0.8 N/A
quizalofop-p-ethyl 2.3 0.68-1.56 WUXI-N4 No inhibition at 20 uM ND
WUXI-N5 No inhibition at 20 uM ND WuXi-N6 11% inhibition at 20 uM-
pH ND 8.0/17% inhibition at 20 uM- pH 8.5 WuXi-N7 18% at 20 uM ND
WuXi-N8 40% inhibition at 20 uM- pH ND 8.0/47% inhibition at 20 uM-
pH 8.5
Example 6--In Vivo Protein Plasma Binding Assays of
Arylphenoxypropionate Derivatives
[0084] Protein plasma binding assays were conducted in female mice
for each of the arylphenoxypropionate derivatives quizalofop-p,
quizalofop-p-ethyl, fenoxaprop-p, and fenoxaprop-p-ethyl.
[0085] Results are summarized in Table 3 below. Due to plasma
esterase activity, quizalofop-p-ethyl and fenoxaprop-p-ethyl were
not stable under assay conditions, and the carboxylic acid
equivalents were quantified instead.
TABLE-US-00004 TABLE 4 Plasma Protein Binding Assay Data for
Representative Arylphenoxypropionate Derivatives Percentage of
Percentage of Compound Compound Bound Compound Recovered
quizalofop-p 96.8% 90% fenoxyfop-p 98.58% 76%
Example 7--In Vivo Pharmacokinetic Studies
[0086] Quizalofop-p-ethyl or quizalofop-p dissolved in
carboxymethylcellulose or canola oil was administered by gavage to
mice at a dosage of 50 mg/kg. For each of the four treatment
groups, blood was harvested from each mouse at 1, 2, 4, and 6 hours
after gavage, and a final blood sample was withdrawn from the mice
at 8, 24, 48 or 72 hours after gavage.
[0087] For each blood sample withdrawn, 50 .mu.L of plasma was
isolated for methanol extraction of quizalofop-p and
quizalofop-p-ethyl. These samples were analyzed by liquid
chromotography in a Bruker micrOTOF Q-II LC/MS. Samples were
quantified using standard calibration curves for both quizalofop-p
and quizalofop-p-ethyl by addition of a known concentration of each
compound to 50 .mu.L of mouse plasma.
[0088] Both quizalofop-p and quizalofop-p-ethyl were detected in
samples. The concentration of quizalofop-p-ethyl detected at all
collection timepoints was much lower than the concentration of
quizalofop-p detected. The peak plasma concentration of
quizalofop-p of 35 .mu.L/mg was detected in blood samples harvested
8 hours after gavage.
[0089] NZ-331 dissolved in polyethylene glycol (PEG) or canola oil
was administered by gavage to mice at a dosage of 100 mg/kg. Blood
was harvested from each mouse at 30 minutes after gavage and a
final sample was withdrawn from the mice at 90 minutes after
gavage. For each blood sample withdrawn, 50 .mu.L of plasma was
isolated for methanol extraction of NZ-331. These samples were
analyzed by liquid chromotography in a Bruker micrOTOF Q-II LC/MS.
Samples were quantified using standard calibration curves for
NZ-331 by addition of a known concentration of the compound to 50
.mu.L of mouse plasma.
[0090] FIG. 4 illustrates the plasma concentration of NZ-331 in
blood samples collected from mice following administration of
NZ-331 dissolved in polyethylene glycol (PEG) or canola oil by
gavage at a dosage of 100 mg/kg. NZ-331 was detected in the
samples. The peak plasma concentration of NZ-331 detected in blood
samples harvested 30 minutes after gavage was approximately 6
.mu.L/mg and the peak plasma concentration of NZ-331 detected in
blood samples harvested 90 minutes after gavage was 9 .mu.L/mg.
[0091] NZ-332 dissolved in polyethylene glycol (PEG) or canola oil
was administered by gavage to mice at a dosage of 100 mg/kg. Blood
was harvested from each mouse at 30 minutes after gavage and a
final sample was withdrawn from the mice at 90 minutes after
gavage. For each blood sample withdrawn, 50 .mu.L of plasma was
isolated for methanol extraction of NZ-331. These samples were
analyzed by liquid chromotography in a Bruker micrOTOF Q-II LC/MS.
Samples were quantified using standard calibration curves for
NZ-331 by addition of a known concentration of the compound to 50
.mu.L of mouse plasma.
[0092] FIG. 5 illustrates the plasma concentration of NZ-332 in
blood samples collected from mice following administration of
NZ-332 dissolved in polyethylene glycol (PEG) or canola oil by
gavage at a dosage of 100 mg/kg. NZ-332 was detected in the
samples. The peak plasma concentration of NZ-332 detected in blood
samples harvested 30 minutes after gavage was approximately 9
.mu.L/mg and the peak plasma concentration of NZ-332 detected in
blood samples harvested 90 minutes after gavage was 13
.mu.L/mg.
[0093] NZ-331 and NZ-332 dissolved in canola oil was administered
by gavage to mice at a dosage of 200 mg/kg. The first treatment
group received only a single dose. The second and third treatment
groups received two doses administered 8 hours apart. Blood was
harvested from the mice at 1, 2, and 4 hours after gavage, and a
final sample was withdrawn from the mice at 8, 12, and 24 hours
after gavage. Table 4 includes dosage and blood sample harvest data
for this group of mice.
TABLE-US-00005 TABLE 4 NZ-331and NZ-332 dissolved in canola oil was
administered by gavage to mice at a dosage of 200 mg/kg Maximum
tolerated dose: Two doses (8 h apart), 200 mg/Kg, oil, gavage Mouse
Dose time of dose Survival Terminal First dose at t = 0 1 200
mg/kg; 200 ul of 20 mg/ml 0 (9:00 am) 1 (10:00 am) 8 (5:00 pm)
Bleed at t = 1 hour 2 200 mg/kg; 200 ul of 20 mg/ml 0 (9:00 am) 1
(10:00 am) 8 (5:00 pm) Bleed at t = 2 hour 3 200 mg/kg; 200 ul of
20 mg/ml 0 (9:00 am) 1 (10:00 am) 8 (5:00 pm) Bleed at t = 4 hours
4 200 mg/kg; 200 ul of 20 mg/ml 0, 8 (9:00 am, 5:00 pm) 2 (11:00
am) 12 (9:00 pm) Second dose at t = 8 hours 5 200 mg/kg; 200 ul of
20 mg/ml 0, 8 (9:00 am, 5:00 pm) 2 (11:00 am) 12 (9:00 pm) Bleed at
t = 8 hours 6 200 mg/kg; 200 ul of 20 mg/ml 0, 8 (9:00 am, 5:00 pm)
2 (11:00 am) 12 (9:00 pm) Bleed at t = 12 hours 7 200 mg/kg; 200 ul
of 20 mg/ml 0, 8 (9:00 am, 5:00 pm) 4 (1:00) 24 (9:00 am) Bleed at
t = 24 hours 8 200 mg/kg; 200 ul of 20 mg/ml 0, 8 (9:00 am, 5:00
pm) 4 (1:00) 24 (9:00 am) 9 200 mg/kg; 200 ul of 20 mg/ml 0, 8
(9:00 am, 5:00 pm) 4 (1:00) 24 (9:00 am) 10 200 mg/kg; 200 ul of 20
mg/ml 0, 8 (9:00 am, 5:00 pm) extra extra
[0094] For each blood sample withdrawn, 50 .mu.L of plasma was
isolated for methanol extraction of NZ-331 and NZ-332. These
samples were analyzed by liquid chromotography in a Bruker micrOTOF
Q-II LC/MS. Samples were quantified using standard calibration
curves for NZ-331 and NZ-332 by addition of a known concentration
of the compounds to 50 .mu.L of mouse plasma.
[0095] FIG. 6A illustrates the plasma concentration of NZ-331 and
NZ-332 in blood samples collected from mice following
administration of two doses of NZ-331 and NZ-332 dissolved in
canola oil by gavage at a dosage of 200 mg/kg. Both NZ-331 and
NZ-332 were detected in the samples. The peak plasma concentration
of NZ-331 detected was approximately 23 .mu.L/mg in blood samples
harvested approximately 12 hours after administration of the first
dose by gavage and approximately 4 hours after administration of
the second dose by gavage. The peak plasma concentration of NZ-332
detected was approximately 34 .mu.L/mg in blood samples harvested
approximately 12 hours after administration of the first dose by
gavage and approximately 4 hours after administration of the second
dose by gavage.
[0096] FIG. 6B illustrates the corrected plasma concentration of
NZ-331 in blood samples collected from mice following
administration of two doses of NZ-331 and NZ-332 dissolved in
canola oil by gavage at a dosage of 200 mg/kg. The peak plasma
concentration of NZ-331 detected was approximately 138 .mu.L/mg in
blood samples harvested approximately 24 hours after administration
of the first dose by gavage and approximately 16 hours after
administration of the second dose by gavage.
[0097] NZ-313 dissolved in canola oil was administered by gavage to
mice at a dosage of 100 mg/kg. Two doses were administered 4 hours
apart. Blood was harvested from each mouse at 30 minutes, 90
minutes, and 5 hours after gavage and a final sample was withdrawn
from the mice at 4, 8, and 12 hours after gavage. For each blood
sample withdrawn, 50 .mu.L of plasma was isolated for methanol
extraction of NZ-313. These samples were analyzed by liquid
chromotography in a Bruker micrOTOF Q-II LC/MS. Samples were
quantified using standard calibration curves for NZ-313 by addition
of a known concentration of the compound to 50 .mu.L of mouse
plasma.
[0098] FIG. 7 illustrates the plasma concentration of NZ-313 in
blood samples collected from mice following administration of two
doses of NZ-313 dissolved in canola oil by gavage at a dosage of
100 mg/kg. NZ-313 was detected in the samples. The peak plasma
concentration of NZ-313 detected was approximately 0.69 .mu.L/mg in
blood samples harvested at 30 minutes after gavage.
[0099] NZ-313 dissolved in polyethelyne glycol (PEG) was
administered by gavage to mice at a dosage of 200 mg/kg. Blood was
harvested from each mouse at 30 minutes after gavage and a final
sample was withdrawn from the mice at 90 minutes after gavage. For
each blood sample withdrawn, 50 .mu.L of plasma was isolated for
methanol extraction of NZ-313. These samples were analyzed by
liquid chromotography in a Bruker micrOTOF Q-II LC/MS. Samples were
quantified using standard calibration curves for NZ-313 by addition
of a known concentration of the compound to 50 .mu.L of mouse
plasma.
[0100] FIG. 8 illustrates the plasma concentration of NZ-313 in
blood samples collected from mice following administration of a
single dose of NZ-313 dissolved in polyethylene glycol (PEG) by
gavage at a dosage of 200 mg/kg. NZ-313 was detected in the
samples. The peak plasma concentration of NZ-313 detected was 1
.mu.L/mg in blood samples harvested at 90 minutes after gavage.
[0101] FIG. 9 provides a comparison of the plasma concentrations of
NZ-313, NZ-313 acid, NZ-313 glucuronidated, NZ331, and NZ-332 in
blood samples collected from mice following administration of a
single dose of the following compounds by gavage at a dosage of 100
mg/kg: NZ313 dissolved in polyethylene glycol (PEG), NZ-313 acid
dissolved in polyethylene glycol (PEG), NZ-313 glucuronidated
polyethylene glycol (PEG), NZ-331 dissolved in polyethylene glycol
(PEG) or canola oil, or NZ-332 dissolved in polyethylene glycol
(PEG) or canola oil.
[0102] NZ-3369 dissolved in canola oil was administered by gavage
to mice at a dosage of 200 mg/kg. Blood was harvested from each
mouse at 1, 2, and 4 hours after gavage and a final sample was
withdrawn from the mice at 8 hours after gavage. For each blood
sample withdrawn, 50 .mu.L of plasma was isolated for methanol
extraction of NZ-369. These samples were analyzed by liquid
chromotography in a Bruker micrOTOF Q-II LC/MS. Samples were
quantified using standard calibration curves for NZ-369 by addition
of a known concentration of the compound to 50 .mu.L of mouse
plasma.
[0103] FIG. 10 illustrates the plasma concentration of NZ-369 in
blood samples collected from mice following administration of a
single dose of NZ-369 dissolved in canola oil by gavage at a dosage
of 200 mg/kg. NZ-313 was detected in the samples. The peak plasma
concentration of NZ-369 detected was 27.4 .mu.L/mg in blood samples
harvested at 2 hours after gavage.
[0104] FIG. 11 provides a comparison of the plasma concentrations
NZ-331, NZ-332, and NZ-369 in blood samples collected from mice
following administration of two doses of NZ-331, NZ-332, and NZ-369
dissolved in canola oil at a dosage of 200 mg/kg 8 hours apart. The
peak plasma concentration of NZ-331 detected was 34.5 .mu.L/mg in
blood samples harvested at 24 hours after gavage. The peak plasma
concentration of NZ-332 detected was 65.3.5 .mu.L/mg in blood
samples harvested at 12 hours after gavage. The peak plasma
concentration of NZ-369 detected was 27.4 .mu.L/mg in blood samples
harvested at 2 hours after gavage.
[0105] NZ-331, NZ-332, and NZ-369 dissolved in canola oil was
administered by gavage to mice once per day for four days at a
dosage of 200 mg/kg, 100 mg/kg, and 100 mg/kg, respectively. Blood
was harvested from each mouse 24 hours after the first dose and 24
hours after the last dose. Table 5 includes plasma concentration
data for these mice.
TABLE-US-00006 TABLE 5 Plasma concentration of NZ-331, NZ-332, and
NZ-369 following administration of each compound once per day for
four days Oral Dose Plasma conc. Plasma conc. [1 dose/day] X 24
Hrs. after 24 Hrs. after Compound 4 days 1.sup.st dose last dose
NZ-331 200 mg/kg 17.7 (.+-.2.7) .mu.g/ml 27.1 (.+-.13.7) .mu.g/ml
NZ-332 100 mg/kg 2.2 (.+-.0.6) .mu.g/ml 1.8 (.+-.0.2) .mu.g/ml
NZ-369 100 mg/kg 0.74 (.+-.0.09) .mu.g/ml 0.57 (.+-.0.07)
.mu.g/ml
[0106] Additional pharmacokinetic studies of quizalofop-p-ethyl and
fenoxaprop-p-ethyl were conducted in rats.
[0107] Quizalofop-ethyl was absorbed to a considerable extent by
the oral route. Much of what is absorbed is returned to the
gastrointestinal tract in bile. Peak blood concentrations occur six
to nine hours after exposure, and decline with a half life of round
20 to 30 hours. Quizalofop-ethyl is metabolized to a number of
products and distributed to every tissue sampled. Quizalofop-p
ethyl converts from ester to acid in .about.3 h.
[0108] Fenoxaprop-P-ethyl was absorbed rapidly in male and female
rats. The test substance was already found in the blood 15 minutes
after a single oral administration. The maximum concentration was
reached at about 6-8 hours after application. Lowering of the blood
concentrations was biphasic with a half-life of 9-11 hours for the
initial phase and a half-life of 68-75 hours for the terminal
phase. Pharmacokinetic investigation of blood levels revealed
practically zero difference between the dose levels of 2 and 10
mg/kg, which were administered as a single dose by oral gavage. The
minimum rate of absorption (urinary excretion including cages
washes and residues in tissues/organs) was generally higher in
females than in males and reached at least 40% of the administered
dose.
Example 8--Toxicity Testing
[0109] S. cerevisiae cytotoxicity and human fibroblast cytotoxicity
testing was performed. The following compounds were not toxic at
concentrations at or above 100 .mu.M in both S. cerevisiae
cytotoxicity and human fibroblast cytotoxicity testing: NZ-251,
NZ-274, NZ-287, NZ-289, NZ-290, NZ-293, NZ-294, NZ-295, NZ-296,
NZ-298, NZ-299, NZ-300, NZ-301, NZ-302, NZ-304, NZ-305, NZ-306,
NZ-307, NZ-308, NZ-309, NZ-310, NZ-311, NZ-312, NZ-313, NZ-314,
NZ-315, NZ-316, NZ-317, NZ-318, NZ-319, NZ-320, NZ-321, NZ-322,
NZ-323, NZ-325, NZ-326, NZ-327, NZ-328, NZ-329, NZ-330, NZ-331,
NZ-332, NZ-334, NZ-335, NZ-337. NZ-361, NZ-362, NZ-363, NZ-364,
NZ-369, NZ-370, NZ-371. NZ-373, NZ-374, NZ-376, NZ-377, NZ-378,
NZ-379, NZ-380, NZ-381, NZ-383, NZ-385, NZ-386, NZ-387, NZ-388,
NZ-389, NZ-390, NZ-391, NZ-392, NZ-393, NZ-394, NZ-395, NZ-396,
NZ-397, NZ-398, NZ-399, NZ-400, NZ-401, NZ-402.
[0110] The following compounds were not toxic at concentrations at
or above 100 .mu.M in S. cerevisiae cytotoxicity testing: NZ-347,
NZ-349, NZ-350, NZ-351, NZ-353, NZ-355, NZ-356, NZ-357, NZ-358,
NZ-359, NZ-360, NZ-372.
[0111] The following compounds were not toxic at concentrations at
or above 100 .mu.M in human fibroblast cytotoxicity testing:
NZ-303, NZ-338, NZ-341, NZ-342, NZ-343, NZ-345, NZ-346, NZ-368,
NZ-365, NZ-382, fenoxaprop-p, fenoxaprop-p-ethyl.
[0112] The following compounds were not toxic at concentrations at
or above 25 .mu.M and at or below 50 .mu.M in s. cerevisiae
cytotoxicity testing: NZ-348, NZ-352, NZ-366, NZ-368.
[0113] The following compound was not toxic at concentrations at or
above 25 .mu.M and at or below 50 .mu.M in human fibroblast
cytotoxicity testing: NZ-366.
[0114] The following compounds were not toxic at concentrations at
or above 50 .mu.M and at or below 100 .mu.M in s. cerevisiae
cytotoxicity testing: NZ-336, NZ-354, NZ-365, NZ-382.
[0115] The following compound was not toxic at concentrations at or
above 50 .mu.M and at or below 100 .mu.M in human fibroblast
cytotoxicity testing: NZ-336.
Example 9--Synthesis of Aryloxyphenoxyacetate Derivatives
[0116] Aryloxyphenoxyacetate derivatives can be prepared according
the following scheme:
##STR00189##
[0117] The compounds (3) are synthesized by condensation of
hydroquinone (1) with chloro- or bromo-substituted acetate (2) at a
temperature range from 5.degree. C. to 120.degree. C. in water, or
organic solvent, such as DMF, DMSO, ethanol, in the presence of
base, such as NaOH, K.sub.2CO.sub.3, or NaH. Substitution of
compounds (3) with aromatic chloride or bromide (R4-X) in organic
solvent, such as DMF, DMSO, dioxane, acetonitril, ethanol in the
presence or absence of a catalyst, such as CuI, at a temperature
range from 25.degree. C. to 150.degree. C. in the presence of base,
such as K.sub.2CO.sub.3. Li.sub.2CO.sub.3, LiOH, KOH, produces
ester (4). Hydrolysis of ester (4) will give acid (5). Coupling of
acid (5) with amine in the presence of coupling reagents, such as
EDCI, CDI or via acyl chloride in organic solvent, such as DCM,
THF, DMF, produces amide (6).
[0118] Other aryloxyphenoxy or aryloxyphenyl-acetate, -acetyl
amide, -acyl sulfonamide can be prepared by similar methods. It is
apparent to one skilled in art that other sequence of the reaction,
and alternative reagents can be used for the synthesis of compounds
of the present disclosure. These alternatives for the synthesis of
the derivatives are within the scope of this invention.
[0119] Although only exemplary embodiments of the invention are
specifically described above, it will be appreciated that
modifications and variations of these examples are possible without
departing from the spirit and intended scope of the invention. For
example, various specific formulations including components not
listed herein and specific methods of administering such
formulations may be developed using the ordinary skill in the art.
Numeric amounts expressed herein will be understood by one of
ordinary skill in the art to include amounts that are approximately
or about those expressed. Furthermore, the term "or" as used herein
is not intended to express exclusive options (either/or) unless the
context specifically indicates that exclusivity is required; rather
"or" is intended to be inclusive (and/or).
Sequence CWU 1
1
2140DNAArtificial SequenceSynthetic oligonucleotide 1agatgaagcc
atatgacaat catggccccc gaggcggttg 40236DNAArtificial
SequenceSynthetic oligonucleotide 2agagtaagct tacagcggga tgttcttgag
gcggcc 36
* * * * *
References